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The physical stability of guaifenesin in melt-extruded acrylic matrix 
tablets was investigated. The initial study found that recrystallization was caused 
by guaifenesin supersaturation in Eudragit®L100-55, and that the instability was 
confined to tablet surfaces. Drug release was not affected by crystal growth as 
guaifenesin is very water soluble. The addition of a polymer in which guaifenesin 
showed a higher solubility to the matrix blend decreased  recrystallization on 
storage as supersaturation levels dropped.   
The second investigation identified heterogeneous nucleation as an 
additional factor in guaifenesin recrystallization. A quantitative assay showed that 
talc in matrix tablets accelerated the onset and extent of the recrystallization due 
to a nucleating effect on guaifenesin.  Storage under elevated humidity conditions 
promoted recrystallization as well, but crystal growth was not correlated with 
water uptake, which implied a nucleating effect of moisture on guaifenesin. 
 viii 
The third study investigated the effect of aqueous film-coating of the 
matrix tablets to stabilize amorphous guaifenesin using either hypromellose or 
ethylcellulose as coating polymers. The selection of the coating polymer 
influenced crystal morphology, and was a major factor in delaying the onset of 
crystallization, ranging from 1-3 weeks (ethylcellulose film-coatings) to 3-6 
months (hypromellose film-coatings). Higher weight gains retarded 
recrystallization. Factors promoting drug and polymer diffusion, such as long 
curing times and elevated temperatures during both curing and storage, 
incomplete film coalescence and high core drug concentrations all resulted in an 
earlier onset of crystallization. 
The effects of single-screw extrusion (SSE) and twin-screw extrusion 
(TSE) of diltiazem hydrochloride and guaifenesin-containing blends in 
Eudragit®L100-55 on drug morphology and dispersion were studied in the fourth 
project. Guaifenesin solubilized diltiazem hydrochloride, and plasticized 
Eudragit®L100-55. Extrusion temperature influenced the drug morphology in 
single-screw extrudates, while TSE rendered all formulations amorphous due to 
higher dispersive mixing capabilities. Drug distribution improved with extrusion 
temperature and by TSE over SSE. Homogeneous matrices showed the slowest 
drug release at pH 1.0. Recrystallization was inversely correlated to drug 
distribution. 
In conclusion, the physical stability of guaifenesin in hot melt-extruded 
acrylic matrix tablets was shown to be affected by formulation, processing and 
post-processing factors.  
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Chapter 1: The stability of composites made by thermal processing 
1.1 INTRODUCTION 
 
The stability of pharmaceutical products can be expressed in numerous forms, 
reflecting the many possible consequences of instabilities in pharmaceutical products [1]. 
The properties of thermally processed dosage forms are a combination of the effects of 
processing parameters, formulation components, storage conditions and possible 
interaction between these factors. The purpose of the following text is to give an 
overview over parameters affecting the chemical and physical stability of thermally 
processed formulations, and to show how the performance of a thermally processed 
dosage form can be influenced by processing and formulation factors. The discussion will 
center on hot-melt extrusion [2].  
 
1.2 STABILITY ISSUES WITH DRUG SUBSTANCES 
 
1.2.1 Chemical Stability of drug substances 
 
Drugs are subject to degradation reactions based on their chemical structure and 
the environment they reside in. Drug degradation reactions are discussed in several 
books, for instance Carstenson [1], Yoshioka [3] and Baertschi [4]. Common degradation 
reactions are hydrolysis, dehydration, elimination reactions such as decarboxylations, and 
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oxidation reactions. Instabilities manifest themselves in a decreased drug concentrations 
and shifting content uniformity, changes in product appearance and performance 
parameters.  
 
Decomposition reactions are often complex, with several reactions possible or 
competing, depending on the prevailing conditions. Byrn et al identify molecular 
mobility and mechanical stress as major factors influencing solid state reactivity [5], 
which prepare the environment for chemical reactions. Mechanical stress can increase the 
surface area, the number of defects and the amount of amorphous material present at the 
site. Molecular mobility is necessary for molecular rearrangement in connection with 
chemical or physical decomposition reactions. Temperature, pH, ionic strength, as well as 
the presence of moisture, oxygen and other compounds are then the main factors 
determining the type and extent of reactions taking place, manifesting the instability [3]. 
 
1.2.2 Influence of temperature on the stability of drug substances 
 
One of the main factors in drug stability is temperature, and the Arrhenius 
equation has been traditionally used to describe the relationship between the temperature 
and the rate constant of degradation reactions [3]. Yoshioka discusses additional 
equations describing temperature-degradation rate relationships. As chemical reactions 
generally proceed faster at elevated temperatures, thermal processing inherently carries a 
higher potential for unwanted reactions. In addition, the prediction of events is 
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complicated by the state changes the blend components undergo during thermal 
processing. The substances may be solid for parts of the process. Some substances melt, 
others soften, components dissolve in one another, and the mixture experiences 
mechanical stress at the same time. The conditions for reactions change throughout the 
process, as the melt viscosity and the pressure in the barrel change. After extrusion, the 
return to a solid state varies with the cooling rate. Cooling after melt extrusion can trap 
metastable forms, which can then slowly transition to a more stable formation. The 
resulting reactions are complex. Carstensen [1] discusses solid state reactions, including 
the kinetics of instability reactions resulting in liquids and gases.  
 
1.2.3  Oxidative stability of drug substances 
 
Oxidation reactions depend on the presence of oxygen, and are often catalyzed by 
metal ions. Autoxidation involving reactive oxygen-species are often catalyzed by 
impurities, and may be hard to reproduce [6]. Oxygen susceptibility testing of the drug 
can yield mechanisms of degradation which can be used to predict the “natural” 
oxidation, to form the basis for preventive measures [6]. Stabilization can be achieved by 
restricting the amount of oxygen in contact with the dosage form, either by keeping the 
product in an inert gas atmosphere, or by using oxygen-barrier packaging and  




Due to oxidation reaction kinetics, extrapolation of reaction rates can be difficult. 
Thermo-oxidative stability testing characterizes the behavior of materials when streesed 
by both heat and oxygen [7]. The presence of moisture will contribute to additional 
mechanisms of degradation.  
 
1.2.4  Physical Stability of drug substances 
 
The physical stability of a drug comprises several aspects [3]. Compounds can 
change between the amorphous and the crystalline state. Because the morphological 
states differ in their properties, the performance of the dosage form can be affected. 
Stresses involved in manufacturing unit operations can induce transitions in either 
direction (see discussion in section 6.3.). Excipients can be used to stabilize an 
amorphous state [8], and formulation components or impurities can induce nucleation and 
crystal growth. Crystallization from the amorphous state can be localized [9]. 
 
Polymorphic changes occur when the drug transforms from one polymorphic 
form into another. These transformations are driven by changes in the temperature and 
the pressure the substance is exposed to. For any combination of temperature and 
pressure, one polymorph is the most stable. Like crystalline-amorphous transitions, 




In addition to changes in the crystal structure, crystals can incorporate water or 
solvents, as hydrates or solvates, respectively. When the type or number of these 
associated molecules change, but not the crystal structure they are attached to, the 
alteration is known as a pseudopolymorphic transformation.  
 
Crystals are not static, and changes in crystal dimensions present another physical 
instability. A wide particle size distribution is associated with Ostwald ripening, as 
smaller crystals dissolve, and the material is deposited onto larger crystals, which 
consequently grow further in size. The increase in average particle size is also known as 
coarsening.  
 
The physical changes and stabilization strategies for amorphous pharmaceutical 
solids are discussed by Yu [8]. Excipients can stabilize the amorphous state by 
immobilization and isolation, and by direct interactions, for instance hydrogen-bonding, 
with the amorphous compound. The stabilizing excipients themselves may have to be 
protected from crystallization, and their stability against oxidation and hydrolysis is 







1.3  STABILITY OF POLYMERS 
 
1.3.1  Chemical stability of polymers 
 
Polymer stability is as crucial as API stability to arrive at stable formulations. 
Allen et al [10] and Bicerano [11] discuss the how the stability of polymers is related to 
their structure. Alexy et al [12] investigated the stability of poly(vinyl alcohols) during 
melt extrusion. The degree of hydrolysis, number of double bonds and heterogeneities 
increased the susceptibility to degradation during melt extrusion via an acid autocatalysis 
mechanism. Stability was increased by incorporating benzoic acid as a stabilizer.  
 
Polymer composition and structure influence its stability. The strength of valence 
bonds between the elements making up the polymer backbone influence the chain 
stability.  Common polymers can be grouped according to their relative stability based on 
the strength of valence bonds. Unsaturated bonds are susceptible to oxidation and bond 
strength is important for side chain stability as well. The weak carbon-chlorine bond 
contributes to thermal instability of PVC. While all carbon-hydrogen bonds are 
susceptible to oxidation, the carbon’s hybridization state determines the degree of 
instability, as the hydrogen is abstracted more easily from a tertiary than a primary 
carbon. The backbone rigidity increases polymer stability. Polymers with aromatic rings, 




Depolymerization, or chain scission, is a major effect of polymer instability, 
which reduces the molecular weight of a polymer. As the molecular weight influences 
major polymer properties necessary for processing, product quality and performance, 
MW is a common experimental parameter. The practical significance of molecular 
weight reduction likely decreases for higher MW, since the reduction in MW is lower 
compared to the polymer chain  length. However, there may be critical MW levels, at 
which the properties of a polymer change disproportionally. Depolymerization can occur 
during processing or in storage. Viljanmaa et al report depolymerization depending on 
storage temperature, with molecular weight decreasing 29% at -18˚C and 50% at room 
temperature after 56 days [13]. Stabilization was achieved by end-capping the polymers 
chains, which slowed degradation during storage. A polymer can also be changed by 
crosslinking, which increases the molecular weight.  
 
Other degradation reactions are elimination and substitution reactions [10]. 
Elimination reactions result in small molecules which do not resemble the monomer, for 
instance water, or hydrochloric acid. The presence of these reaction products can in turn 
contribute further to instability. Substitution reactions change the side chains of a 
polymer, which can affect the polymer properties.  
 
Degradation reactions depend on the immediate environment. In a processed 
polymer blend contains several phases, instabilities can vary by phase. Tocháček et al 
[14] were able to distinguish between different degradation reactions in different phases 
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of the polymer after multiple extrusions. Backbone cleavage was found in the 
polypropylene homopolymer phase, while crosslinking occurred in the rubbery phase 
containing ethylene-propylene rubber and polyethylene homopolymer. The effects of 
these reactions are the opposite of each other, as cleavage reduces the molecular weight 
while crosslinking increases it.   
 
1.3.2  Oxidative stabilization of polymers 
 
Oxidative reactions can be induced by impurities in the polymer, such as residual 
monomer, catalyst, metal ions, byproducts and structural irregularities. Preventive 
stabilization aims to reduce oxidation by removing these compounds from the bulk 
matter. Compendial purity standards take this approach, although practical limits apply.  
 
In arrestive stabilization, the sources of instability are inactivated or removed by 
adding compounds that possess reactive sites that preferentially react, or form reaction 
products that have greater stability than a product formed with the polymer. Antioxidants 
can be added to the formulation to stabilize the polymer. In addition to being 
pharmaceutically acceptable, the effects of specific antioxidant(s) on the polymer 
stabilization, the thermal process and the other formulation components have to be taken 
into consideration. Antioxidants can be combined, preferably to act synergistically. For a 
discussion of antioxidants in general, see Allen [10], Crowley discusses antioxidants in 
melt extrusion applications [15].  
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Polymer structure contributes to oxidative stability in polymers. Unsaturated 
bonds are prone to oxidation, and hydrogen is more reactive in radical reactions if bound 
to tertiary carbon, which is the result of branching. Higher crystallinity decreases 
oxidation due to the higher density of the samples [10].  Hoang et al [16] reported that 
initial vinyl unsaturation and short chain branch content correlated with induction times 
for oxidative instability in metallocene polyethylenes. In addition, multiple degradation 
reactions were detected, radical crosslinking reactions, formation of conjugated system, 
and discolorations due to catalyst residues, illustrating the complexity of degradations.  
 
The chemical stability of PEO was investigated by Crowley et al [17]. The 
antioxidants, even when working by the same basic mechanism, had to be screened for 
their compatibility with the system and influenced the drug release rate. These results 
indicated that the choice of antioxidant for a formulation should be carefully considered.  
 
1.3.3  Physical stability of polymers 
 
Another aspect contributing to the stability and properties of polymers is their 
physical state. Some polymers are always amorphous, while others can exist in 
semicrystalline forms with varying degrees of amorphous material. In the semicrystalline 
state, parts of the polymer chains are arranged in ordered domains, which are interspersed 
with areas of amorphous structure. A single macromolecule will pass through many 
crystalline regions [18]. Morphological changes between amorphous and crystalline 
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polymers vary above the glass transition temperature. Solid amorphous polymers pass 
through rubbery, gumlike stages to the liquid state, while crystalline polymers retain their 
structure up to the melting temperature of the crystallites, where a rapid transition to a 
liquid state occurs [19]. If the temperature is raised further, polymers eventually undergo 
thermal decomposition. Thermal processing occurs above the Tg, at a temperature when 
the melt viscosity is low enough for processing. Consequently, crystalline polymers have 
a narrower window for processing, as they have to be heated not only above their Tg, but 
above their melting temperature as well, which brings the processing temperature closer 
to the decomposition temperature [20]. 
 
Both formulation and processing factors influence the crystallinity of polymers 
[21]. Nucleating agents decrease the surface free energy barrier to nucleation. Plasticizers 
enhance chain mobility and lower the energy required for the chain folding process. 
Processing conditions, especially process temperature and duration also influence 
polymer crystallization. Nucleating agents are diverse compounds, including low 
molecular weight organics that crystallize themselves before nucleating the polymer [22], 
and have been found to work by several mechanisms. Li et al describe classes of 
nucleating agents and their respective nucleating mechanisms for poly(lactic acid). The 
group reported that the combination of plasticizer and nucleating agent was necessary to 
maximize crystallization of poly(lactic acid) [21], but the processing temperature of the 
injection molding process continued to have a large influence on the product quality. The 
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effect of nucleating agents on crystallization kinetics of polymers was described by 
Aliotta et al [23].  
 
Crystallinity of polymers can change with degradation [24]. Amorphous regions 
generally erode faster, increasing the percentage of crystallinity. Amorphous samples can 
recrystallize if water from the erosion medium lowers the glass transition temperature. 
One example is the recrystallization of the amorphous phase of a poly(L-lactide) and 
poly(ε-caprolactone) blend due to the low glass transition temperature of the blend. The 
recrystallization caused brittleness and shrinking of the films which decreased their 
adhesion properties [13]. Crystallinity influences many polymer properties, such as the 
response to mechanical stresses and the solubility. 
 
1.4  STABILITY OF OTHER MATRIX FORMERS 
 
Fats and waxes have been used in thermal processes [25]. Usually they are complex 
mixtures, and show changes during storage (“aging”) in their physical structure, which 
manifests itself by increase in crystallinity, or polymorphic changes which affect the 
dosage form properties. The increase in melting point (“hardening”) of triglyceride-
containing suppositories has been associated with polymorphic changes of suppository 
bases [26], although concurrent amorphous-to-crystalline as well as polymorphic 
transitions are also possible [27]. Gelucires are mixtures of polyethylene glycol esters of 
fatty acids and glycerides, distinguished by melting points and HLB values, which have 
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been used to make solid dispersions [28]. Khan and Craig investigated the physical 
stability of these lipids in melt-derived tablets containing paracetamol and caffeine [29]. 
Crystals of fat (“blooming”) developed on tablet surfaces, and their development was 
influenced by storage temperature and the type of drug. The physical integrity of the 
tablets rather than the molecular arrangement of the matrix former was altered, causing 
an increase in dissolution rate on storage. The effects of aging differed by Gelucire grade 
[30]. Choy et al replicated the increased dissolution due to aging, which lead to 
accelerated drug release in-vivo, but found that the extent of absorption was no affected 
[31]. 
 
1.5  FORMULATION DEVELOPMENT AFFECTING STABILITY 
 
One approach to address potential changes should commence with the definition of 
the vulnerabilities of an active component. Which instabilities (degradation, 
crystallization, polymorphic changes) is the drug prone to in view of the intended 
processing methods, and to what extent? What is the desired form for the active? What 
are timescales involved? Does the desired form need to be stabilized? The excipients 
selection should assure processability of the blend as well as in-process and long-term 
stability of the dosage form in addition to the desired performance attributes. 
 
In practice, performing preformulation studies [32], including the exposure to 
stresses encountered during processing, will characterize the drug well enough to set 
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limits, or at least a safety zone, within which the drug, excipients and the blend are stable. 
Important data to gather include decomposition temperatures (e.g. by TGA), melt and 
glass transition temperatures (DSC and MDSC), crystallization kinetics, the solubility of 
the drug (or other components) in the matrix former(s), including possible plasticization 
effects. Energy-temperature diagrams permit the prediction of relative physicochemical 
parameters of polymorphs [33]. 
 
Polymer degradation, and hence drug release, can be influenced by formulation 
[24, 34]. PH-regulating excipients influence matrix hydrolysis, low molecular weight 
compounds affect the hydrophilicity of the dosage form, and the matrix structure can be 
changed by copolymerization and the blending of several polymers. 
 
1.5.1  Excipients influence API stability  
 
Melt-extruded formulations commonly contain other components in addition to 
the active ingredient. The matrix former melts or softens during extrusion, encompassing 
all other components to form the matrix. Other components include plasticizers, often 
necessary to process the matrix former, excipients modulating the drug release or the 
stabilizing the drug’s state, as well as thermal glidants, flow aids, pigments, stabilizers 
and others. The stability of the drug (or any formulation component) in the dosage form 
may be lower than in the bulk substance, and several decomposition reactions may occur 
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simultaneously, as demonstrated in compressed tablets by de Medeiros [35] and de Souza 
[36].  
 
Other formulation components can interfere with a compound’s stability by 
several mechanisms [3]. They can be reactants in chemical reactions, which is fairly 
specific to the substances involved. Excipients can also be a source of moisture, which 
contributes to many degradation reactions as discussed by Yoshika [3]. Hygroscopic 
excipients can increase the moisture content in the matrix on storage, unless this is 
prevented by packaging. Blends of ethylcellulose and hydrophilic polymers 
(hypromellose) to modify drug release were studied by de Brabander [37]. A high 
concentration of hydrophilic polymer in the ethylcellulose matrix correlated with lower 
storage stability over 12 months. Conversely, excipients (colloidal silica, silica gel) which 
bind water tightly may decrease the amount of free water able to participate in 
degradation reactions. Water can plasticize many substances, which increases the 
molecular mobility of the matrix. This is associated by a higher general reactivity of the 
matrix components. Consequently, limits for moisture levels of all blend components 
should be established and monitored to control this source of instability. Extensive 
studies on the effects of water and steam during extrusion have been collected by the 
food industry, where additional water is introduced as part of the extrusion process [38]. 
Excipients can reduce oxidation reactions by influencing the expansion of product at the 
die. Lower product expansion due to high fat and moisture levels resulted in lower 
oxidation [39].  
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1.5.2  Effects of formulation components on product performance 
 
Formulations are designed to provide stability and protection for the active 
ingredient, among other guiding principles. Interactions between formulation components 
can stabilize the dosage form, while changes due to excipients can induce drug 
instabilities. Opposing effects on product quality by different components of the blend 
force the formulator to find a balance between conflicting objectives. 
 
Drug-polymer interactions and incorporation into rigid matrices can increase the 
physical stability of amorphous drugs. Huang et al demonstrated that a 2 : 1 Eudragit RL 
to ethylcellulose blend containing 11% nifedipine stabilized the amorphous state of the 
drug by an antiplasticizing effect, which increased the glass transition temperature from 
50˚C for the amorphous drug to 115˚C for the solid solution. In addition to reducing the 
molecular mobility, hydrogen bonding between nifedipine molecules was replaced by 
hydrogen bonding between the drug and polymers [40]. The combined effects of the 
immobilization in a rigid polymer glass as well as specific drug-polymer interactions 
stabilized the amorphous state [8]. However, even in the presence of drug-polymer 
interactions, stabilization of the amorphous state of the drug is not assured, and was 
influenced by the storage conditions. In particular, the amorphous state was maintained if 
the product was stored below 10% relative humidity [41].  
 
Schachter et al [42] describe a melt-extruded ketoprofen-PEO system, and 
localized the drug in amorphous domains of the polymer. This localization of the drug 
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resulted in high molecular mobility of the drug (as detected with solid state NMR), which 
improved the drug’s dissolution rates. Drug-polymer hydrogen bonding was found both 
in melt-extruded and non-processed physical mixtures. This interaction was used to 
explain the high miscibility and the storage stability of the blends, and enabled processing 
at lower temperatures.  
 
Cooling after melt-extrusion can trap metastable forms, and drug instability can 
be induced by the polymer’s transition to a more stable formation. Prodduturi et al [43] 
studied melt-extruded films containing clotrimazole and poly(ethylene oxide (PEO) and 
reported that the model drug was initially molecularly dispersed in the PEO matrix. After 
extrusion, PEO crystallized in metastable, folded-chain crystallites, but within one month 
the PEO chains transformed into the more stable extended-chain crystallites. This, in 
combination with the low glass transition temperature of PEO, resulted in the 
recrystallization of clotrimazole.  
 
Several, sometimes conflicting, objectives guide the choice of polymers to be 
blended in a matrix. Adjusting the solubility of the drug in the matrix can be used to 
prevent amorphous drug from recrystallizing on storage. While optimizing the solubility 
of the drug in the matrix, the blends must be able to be processed by melt extrusion.  In 
addition, the functionality, e.g. drug release characteristics, of the dosage form must be 
preserved. Bruce et al blended hydrophilic polymers with Eudragit L100-55 in order to 
extend the solubility of guaifenesin in melt-extruded matrix tablets [9]. The use of 
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polycarbophil provided the best solubility enhancement, but changed the dissolution 
profile [44]. Prodduturi et al blended PEO and hydroxypropyl cellulose (HPC) in order to 
stabilize clotrimazole in melt extruded films [45]. While the HPC raised the physical 
stability of both clotrimazole and PEO in the films, the bioadhesion and the flexibility of 
PEO films deteriorated with increasing HPC content. An optimum blend was found to 
consist of HPC : PEO : clotrimazole in a ratio of 55:35:10. 
 
Plasticizer influence formulations by their presence as well as their loss from the 
dosage form. The use of carbon dioxide as a plasticizer has been shown to enable the 
extrusion of heat-labile drugs by substantially lowering the necessary extrusion 
temperatures. Verreck et al [46] reduced the percentage of p-aminosalicylic acid 
decomposition by injecting liquid carbon dioxide into the barrel. CO2 functioned as a 
plasticizer in-situ, and evaporated from the melt at the die as the product equilibrated to 
atmospheric pressure.  The transient presence of the plasticizer is an advantage, since it 
allows for higher drug loadings, and prevented changes in the matrix due to the loss of  
plasticizer on storage. The CO2 evaporation shaped the melt into a foam, which eased the 
post-processing milling step, according to Verreck et al.  
 
Plasticizers condition polymers to enable extrusion, and influence the mechanical 
properties of films. If plasticizers volatilize, migrate, leach or otherwise leave the melt-
extruded system, then the properties of the dosage form change. Bruce et al reported an 
influence of plasticizer level on drug dissolution from hot-melt extruded tablets [47]. 
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Repka et al [48] demonstrated the effects of plasticizer loss from hot-melt extruded films. 
The effects of plasticizer loss on dissolution have also been investigated in film coating 
applications [49]. As the plasticizer loss depends on the specific polymer-plasticizer 
combination used, this is another area open for formulation optimization.  
 
Practical consequences of instabilities differ. Ghebremelski et al studied the use of 
surfactants as plasticizers in hot-melt extrudates. The poorly water-soluble compound 
recrystallized during storage in some formulations. Despite this instability, no effect on 
the dissolution rate was observed over 6 months. Bruce et al [9] reported similar results 
for the well water-soluble compound guaifenesin. 
 
1.6  PROCESSING AFFECTING THE STABILITY 
 
Thermal processing will affect the stability of a drug by shaping the environment 
for the compound during extrusion, and by influencing the product quality, which 
determines the environment of the drug for long-term stability. Riaz expounds that a host 
of primary equipment factors (processing temperature, die geometry, extruder type, screw 
speed and configuration) and formulation factors (composition, moisture level and 
particle size) will determine a set of secondary factors: specific mechanical energy, melt 
temperature and pressure. The resulting viscosity and shear values shape the product 
properties [38]. Henrist et al detail effects of process parameters on melt extrudates, and 
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conclude that the maximum barrel temperature was the most critical parameter for their 
study [50]. 
 
For process development, it is useful to define a processing temperature window, 
including the highest temperature the compound can be exposed to without degradation, 
as well as which elevated temperatures it can tolerate for sustained periods, both by itself 
and in the processing blend. Preformulation studies, as discussed above, help to set limits 
for process parameters. 
 
To maximize the stability in processing, several strategies can be explored. 
Processing at low temperature reduces the thermal stress the blend is exposed to, which 
can also be achieved by shortening the exposure time to high temperatures. Excluding 
known factors of instability from the process will also increase drug stability. This can be 
extended to design a process such as to avoiding process-induced changes of the active as 
well as the excipients.  
 
1.6.1  Processing at lower temperatures. 
 
The processing temperature presents a compromise between the ability to 
manufacture the dosage form using a given process and the short-term as well as the 
long-term stability of the product. For melt extrusion, the temperature must be high 
enough to process the matrix former at a reasonable viscosity, but limit any unwanted 
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reactions such as the degradation of the drug and other thermo-labile formulation 
components.  
 
The addition of a plasticizer enables processing at lower temperatures, at reduced 
pressures and with lower melt viscosities, by lowering the glass transition temperature of 
the polymer. Liquid plasticizers, such as citrate esters, have been employed in hot melt 
extrusion. In addition to excipients, drugs such as chlorpheniramine maleate [51, 52], 
ibuprofen [53], guaifenesin [9], indomethacin [52, 53] and excipients such as methyl 
paraben [54] and tartaric acid [55] can plasticize polymers. Transient plasticization was 
achieved by carbon dioxide, which was injected into an extruder during extrusion [13]. 
Preformulation studies should identify the existence and extent of a plasticizing effect on 
any blend component. It is suggestive of additional instability risks, because the 
plasticizing effect is connected to the solubility of a compound on a polymer. Since the 
drug’s solubility is likely to be higher at the elevated extrusion temperature than at the 
storage temperature, the product incorporating a drug that is soluble in the thermal binder 
is at risk for supersaturation-related instabilities. A drug rendered amorphous by the 
process, but is supersaturated in the matrix at the storage temperature can recrystallize on 
storage [9].  
 
Using matrix formers with low melting or softening points reduces the necessary 
processing temperatures. This approach should be carefully weighed against the long-
term stability of the melt-extruded dosage form. Reactions leading to instability depend 
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on the molecular mobility of the components in the matrix at the storage temperature. 
The glass transition temperature (Tg) marks the transition of the polymer from the 
“glassy” state to the ”rubbery” state, and can be measured by several methods, for 
instance by DSC [56]. Mobility dramatically increases above the glass transition 
temperature, and decreases below it. Mobility below the Tg, however, is not reduced to 
zero, and can contribute to instabilities of all matrix components. A larger difference 
between the storage temperature and the matrix Tg(s) translates into less mobility in the 
system. The T0 or Tg-50 K rule refers to the temperature at which the molecular mobility 
in the system goes towards zero. It has been proposed to base the selection of storage 
temperatures on the temperature T0, not the Tg, to minimize instability [8].  
1.6.2  Minimizing exposure time to high temperatures 
 
In twin screw extruders, materials can be added further downstream in the barrel. 
This can be used to shorten the exposure of the drug to the processing temperatures. The 
matrix blend can be melted and blended without regard to the limitations imposed by the 
drug’s thermal or mechanical stability. The active is then added to the conditioned and 
compounded matrix just upstream enough to achieve a uniform blend.  
 
1.6.3  Effects of processing on blend components 
 
Thermal processing impacts the stability of the polymer. Both melt-extrusion as 
well as injection molding caused a decrease in molecular weight of poly(lactic acid) from 
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9096 dalton to below 6000 dalton [57]. The heat treatment of polyanhydride implants 
made by injection molding caused a drop in the molecular weight from 48,485 (control) 
to 7,120 dalton [58]. The selection of polymer grades for thermal processing must take 
that into account. 
 
Processing can cause instability by inducing phase transformations in drugs. 
Morris et al review how solids can change in processing, and consider the time scales of 
transformations relative to time scales of process-induced stress [59]. Zhang et al discuss 
practical approaches to identify and prevent problems associated with in-process 
conversions, and discusses the impact on product quality [60]. In melt-extrusion, the 
potential for process-induced transformations lies in the temperature gradients as well as 
the mechanical stress during extrusion and should be considered during process 
development. Processing and post-processing conditions can be used to stabilize the 
extrudate. Duclos et al demonstrated that a slower cooling rate resulted in the emergence 
of a stable progesterone polymorph in solid dispersions with poly(ethylene glycol) 6000, 
which was physically stable for at least one year [61].  
 
In melt-extrusion, the effect of oxidation reactions on the polymer depends on the 
processing conditions. High levels of oxygen can result in chain scission and lower the 
melt viscosity, while low levels of oxygen can lead to cross-linking, raising the melt 
viscosity [10]. Al-Malaika report that in addition to temperature and shear, the structure 
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of co-monomers determined whether crosslinking reactions or chain scission dominated 
oxidation reactions of polyethylene polymers [62]. 
 
1.6.4  The effects of thermal processing on the product performance 
 
The type of processing directly affects the performance of the product. The 
surface morphology resulting from the processing method was correlated to the integrity 
of the product during long-term dissolution of implants. Rothen-Weinhold et al [57] 
investigated the effect of melt extrusion and injection molding on the in vitro degradation 
of implants containing a somatostatin analogue. No interactions of drug and polymer 
were observed in either sample. The implants differed in molecular weight, degree of 
crystallinity of the polymer, density and surface structure, which resulted in different 
rates of matrix degradation. While slightly more protein degradation occurred during 
injection molding, higher matrix integrity could sustained drug release for longer periods 
of time in injection-molded implants. This was explained by the absence of surface 
defects in injection molding. Gray et al present another study demonstrating that the 
surface morphology of the extrudate directly influences product stability. Initial lipid 
oxidation in starch extrudates containing linoleic acid started near the surface, as 
expected. However, the highest oxidation rates were observed not in the rubbery samples, 




Properties directly related to the processing method influenced the performance of 
powders derived by thermal processing. Melt-extrusion resulted in powders with a lower 
surface area than powders made by solvent co-precipitation (0.13 m2/g versus 6.19 m2/g, 
respectively, measured by multipoint BET). When the powders were suspended in water, 
melt-extruded powders were physically stable for longer than the co-precipitates. The 
lower surface area of melt-extruded powders decreased its exposure to the aqueous 
medium, since water plasticized the system and consequently destabilized the matrix 
[64].  
 
Melt extrusion can create products with a wide range porosities, which vary from 
very low-porosity structures [65] to foams [66]. Fukuda et al developed porous tablets for 
gastroretentive systems. The carbon dioxide generated by thermal decomposition of 
sodium bicarbonate in the softened acrylic polymer resulted in the porous, buoyant 
structure [67]. Riscanu et al describe the development of microporosity in extruded thin 
films during cooling, and subjected the films to cold stretching to develop surface 
porosity [68]. 
 
The micro-structure of extrudates contributes to product stability. Qi et al [69] 
used ATR-FTIR and microthermal analysis to characterize solid dispersions of 
paracetamol in Eudragit E. They found that drug crystals were preferentially located in 
the center, rather than the surface, of extrudate strands. Such localized distribution of 
drug can influence the stability by creating concentration gradients in the extrudates. The 
25 
 
authors commented that several analytical techniques were necessary to properly 
characterize the drug distribution in the extrudates.  
 
Post-processing operations likewise affect product stability. Post-processing heat 
treatment of injection-molded polyanhydride implants containing gentamicin sulfate was 
studied by Deng [58]. Nitrogen protection during the heat treatment correlated with an 
intact implant shape after 25 days of in-vitro dissolution and more delayed drug release. 
The cracking and disintegration of the implant had been correlated with osmotic pressure 
generated by the gentamicin as it dissolves and leaves the implant. The lower stiffness 
and higher flexibility of implants stored under a nitrogen atmosphere resulted in a matrix 
able to accommodate the increased osmotic pressure without cracking, enabling a longer 
drug release from the dosage form. 
 
1.7  CONCLUSION 
 
Thermal processing inherently carries a higher potential for unwanted reactions, 
which are often complex. Degradation reactions of drugs or excipients are based on their 
chemical structure and the environment they reside in, and the chemical stability is 
influenced by temperature, moisture, mechanical stress, other formulation components 
and impurities. Often, the combined impact of several factors determines degradation 
reactions and rates. The physical stability of drugs extends to amorphous-crystalline 
changes, polymorphic and pseudopolymorphic transformations as well as changes in 
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existing crystals. Polymers undergo degradation as well; chain scission and crosslinking 
are the most common manifestations of instability. Semicrystalline polymers undergo 
changes in the ratio of amorphous-to crystalline domains, and generally possess a 
narrower temperature window for processing between their melting point and their 
degradation temperature. Nucleating agents induce and maximize crystallization, either 
controlled as part of the formulation, or as an unwanted effect of blend components or 
impurities. Other matrix formers are fats and waxes, whose main stability problem are 
polymorphic transitions which manifest themselves in the properties of the dosage form. 
Preventive stabilization aims to reduce instability-inducing factors by purifying the bulk 
materials, and arrestive stabilization, generally by using antioxidants, is designed to stop 
degradation reactions as they occur.  
 
Preformulation studies are used to discover vulnerabilities of an active, so that 
formulation and process development can preclude the instabilities. Formulation 
components as well as processing are additional sources of instability. Excipients can 
impact formulation stability by being reactants in degradation reactions, by being a 
source of moisture or by increasing the formulation moisture content. Drugs can be 
stabilized by drug-polymer interactions, and by incorporating them into a rigid matrix, 
which reduces their molecular mobility, and thus reduces their reactivity. Nevertheless, in 
addition to formulation, storage conditions and packaging are an important part of dosage 
form stability by controlling instability-inducing factors such as oxygen, moisture levels 
and temperature. Instability in the formulation can be due to inhomogeneous distribution 
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of the drug as well as by a change in the polymer state during storage. Often, a 
formulation has to fulfill objectives which conflict with the goal of stabilizing the 
stability, and a compromise between stabilizing the drug and other factors has to be 
found. Plasticizers affect formulation stability and influence its performance, especially 
drug release, and a reduction in plasticizer levels on storage can destabilize the 
formulation. The impact of instabilities on dosage form performance has to be 
determined on an individual basis.  
 
Processing shapes the environment for the compound during processing, and 
influences the product quality. To lower thermal stress on the product, processing can 
occur at lower temperature by plasticizing the matrix, using a low-melting matrix former, 
or adding thermally labile compounds late in the process, if possible. However, long-term 
stability can be negatively affected if the storage temperature is too close to the Tg of the 
formulation (T0 or Tg-50 K rule). Thermal processing impacts formulation stability by 
decreasing the molecular weight of the polymer or by process-induced transformations of 
either drug or excipients. The thermal processing as well as post-processing operations 
shape the surface morphology, surface area, porosities and micro-structure of products, 
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Chapter 2: Research Objectives  
2.1.1 Overall Objective 
 
The objective of this study was to investigate the physical stability of hot-melt 
extruded acrylic matrix tablets containing either Eudragit® L100-55 or Acryl-EZE®. The 
instability manifested itself by the recrystallization of the model drug, guaifenesin, from 
the amorphous state. This type of instability is a general concern in solid solutions, and a 
limiting factor in the wider utilization of solid solutions to formulate poorly water-soluble 
drugs. The causes and contributing factors of guaifenesin crystal growth formation were 
investigated to devise strategies to contain and eliminate this source of physical 
instability for this specific model drug, but are applicable to solid solutions in general.  
To meet the overall goal, the study was divided into several supporting objectives.  
2.1.2 Supporting Objectives 
2.1.2.1  Crystal Growth Formation on Melt-Extrudates 
 
To provide the basis for subsequent investigations, the factors influencing the 
growth of guaifenesin crystals on hot-melt extruded matrix tablets containing either 
Acryl-EZE® or Eudragit L100-55® were determined. The first sub-objective was to 
examine the influence of guaifenesin as a model drug on the processing conditions during 
hot-melt extrusion. The second sub-objective characterized the causes, the onset and the 
localization of guaifenesin crystal growth as well as the effect of recrystallization on the 
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drug release properties of melt-extruded tablets. The third sub-objective studied the use 
of hydrophilic polymeric additives as crystal growth inhibitors and their influence on the 
drug release properties of the blended matrix tablets.  
 
2.1.2.2  The Influence of Heterogeneous Nucleation on the Surface Crystallization of 
Guaifenesin from Melt Extrudates Containing Eudragit® L100-55 or 
Acryl-EZE®. 
 
The second objective was to identify additional factors influencing the physical 
stability of guaifenesin in melt extrudates. The first sub-objective quantified the influence 
of talc on the recrystallization of guaifenesin from hot-melt extruded acrylic matrix 
tablets. Secondly, the impact of relative humidity levels during storage on the 
recrystallization of guaifenesin from tablets containing different levels of non-melting 
components was studied, both at constant and cycling relative humidity values. The last 
sub-objective concerned the identity and composition of the crystalline material on the 
tablet surface, and whether it was influenced by talc and relative humidity.   
 
2.1.2.3  The Influence of Aqueous Film-Coating on the Recrystallization of 
Guaifenesin from Hot-Melt Extruded Acrylic Matrix Tablets 
 
The effect of aqueous film-coating of hot-melt extruded matrix tablets on the 
physical stability of guaifenesin was investigated. Two coating polymers were selected 
based on their solubility for guaifenesin, ethylcellulose as a hydrophobic polymer was 
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expected to provide a barrier to the diffusion of hydrophilic guaifenesin due to their 
structural differences. A hypromellose film was thought to slow guaifenesin diffusion 
through the film as it was able to interact with guaifenesin via hydrogen bonding.  
 
The objectives of this study were to investigate the influence of aqueous film-
coating of hot-melt extruded matrix tablets on the physical stability of guaifenesin. The 
effects of polymer type, weight gain, curing time and temperature, storage conditions and 
core drug-to polymer ratio the onset and extent of guaifenesin recrystallization were 
determined. 
 
2.1.2.4  Properties of extruded tablets produced by either single-screw or twin-screw 
melt extrusion 
 
The reciprocal influence of two model drugs and their effect on melt extrusion, as 
well as the extrusion of pre-mixed powder blends on either a single-screw or a twin-
screw extruder and the consequences of mixing efficiency for tablet performance were 
investigated in the final objective. 
 
The sub-objectives were to characterize thermal properties of blends containing 
diltiazem hydrochloride and guaifenesin, to examine drug morphology and drug 
distribution in melt-extruded tablets produced by either single-screw or a twin screw 
extrusion, and to determine the effect of extruder type on the drug content of the 
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extrudates, their dissolution rate, and the recrystallization of guaifenesin from the 








The following materials were used in all studies. Guaifenesin was purchased from 
Spectrum (Gardena, CA), and was used as model drug. Eudragit® L100-55 was donated 
by Evonik Degussa (Piscataway, NJ, particle size 95% below 250 micron).  
 
Hydrophilic polymers employed in supporting objective I, including Kollidon 25 
(PVP K25), Pluracol E 3350 (PEG 3350) and Pluronic F68 (Poloxamer 188), were all 
donated by BASF (Florham Park, NJ). Noveon AA1 (Polycarbophil) was donated by 
Noveon (Cleveland, OH), and Polyox WSR 303 (Poly(ethylene Oxide)) was donated by 
Dow Chemical (Midland, MI). Acryl-EZE® was donated by Colorcon (West Point, PA). 
Ethanol (200 proof) was purchased from AAPER Alcohol and Chemical (Shelbyville, 
KY). The talc (Imperial 500 USP, particle size 4.5 micron) was a gift from Luzenac 
(Centennial, CO). Triethyl citrate (TEC) was kindly donated by Vertellus (Greensboro, 
NC).  
 
The talc employed in the supporting objective II (Imperial 500 USP, particle size 
4.5 micron) was a gift from Luzenac (Centennial, CO). Drierite® (Hammond, Xenia, 
OH) and sodium chloride, ACS reagent (Sigma-Aldrich, St. Louis, MO) were purchased.  
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Acryl-EZE® was donated by Colorcon (West Point, PA). The desiccant Drierite® 
(Hammond, Xenia, OH) was obtained from Fisher Scientific.   
 
In supporting objective III, the melt-extruded tablets were film-coated using 
Opadry® Clear YS-1-7006 (Polymer: hypromellose) and Surelease® (Polymer: 
ethylcellulose), which were donated by Colorcon (West Point, PA). FMC (Philadelphia, 
PA) provided Aquacoat® ECD 30 (Polymer: ethylcellulose). Dibutylsebacate (DBS) was 
used to plasticize ethyl cellulose, and triethylcitrate (TEC) was used to plasticize 
Eudragit® L100-55, both were gifts from Vertellus (Greensboro, NC). Films to 
investigate the solubility in polymers were cast using Ethocel standard 7 Premium (NF 
grade) by Dow Chemical (Midland, MI). 200 proof alcohol (USP grade) was purchased 
from AAPER Alcohol and Chemical Co (Shelbyville, KY). The desiccant Drierite® 
(Hammond, Xenia, OH) was obtained from Fisher Scientific.   
 
 
Diltiazem hydrochloride (DIL) was used as additional model drug in supporting 
objective IV, and was purchased from Spectrum (Gardena, CA). Colloidal silicon dioxide 
(Cab-O-Sil M-5P, Cabot Corporation, Alpharetta, GA, average particle size 0.2-0.3 
micron) was kindly donated by Cabot. The desiccant Drierite® (Hammond, Xenia, OH) 





3.2.1 Tablet Preparation 
 
Tablets were prepared by hot-melt extrusion of the powder blends, followed by 
manual cutting of the extrudate strand. Premixed powder blends were fed into a single 
screw Randcastle extruder (Randcastle Microtruder Model RCP-0750, Cedar Grove, 
NY) equipped with a Nitralloy 135M screw (3:1 compression ratio with flight 
configuration containing feed, compression and mixing sections). The round die had a 
diameter of 6 mm. The three heating zones and the die were equilibrated at the processing 
temperatures for at least 30-40 minutes before extrusion. The extrudates were allowed to 
cool at room temperature for 24 hours in a desiccator before manually cutting tablets.  
 
  The processing temperatures chosen for extrudates containing Acryl-EZE® and 
guaifenesin were 90°C, 95°C, 110°C (zones 1, 2, 3, respectively) and 115°C (die), and 
between 65 and 95°C for extrudates containing Eudragit® L100-55 (supporting objective 
I). In supporting objectives II and III, formulations were extruded at 65, 75, 85 (zones 1, 
2, 3, respectively) and 85°C (die). In supporting objective IV, the first temperature zone 
(feeding section) was set to 65°C for all extrusions, and the remaining two temperature 
zones (melting and metering sections) and the die were set to the same temperature for 
any given extrusion. To extrude guaifenesin-containing tablets, separate extrusions were 
carried out at 65, 75, 85, 95 and 125°C. Tablets for containing guaifenesin and DIL were 
extruded at either 75, 95 or 125°C. Identical powder blends were processed at the same 
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temperatures on a twin-screw extruder, (Haake Minilab II Microcompounder, 
ThermoScientific, Waltham, MA) equipped with a single heating zone, a conical flighted 
screw (L/D ration 7.82-21.9), a water-cooled force-feeder and a round die (diameter 2 
mm). The melt was not circulated through the back-flow channel. 
 
Two in-process parameters, including the barrel pressure and machine current, 
were used to monitor the processability of the blends. The barrel pressure is the pressure 
exerted by the molten formulation inside the barrel; the machine current is the energy 
required to maintain the screw at a constant speed.  
3.2.2 Film Coating (supportive objective II) 
 
Film coating was applied to study the effect of the film coating on the physical 
stability of guaifenesin in melt-extruded matrix tablets. Hot-melt extruded tablets were 
mixed with compressed placebo tablets up to a 1:1 weight ratio, and 300 gram batches 
(placebo plus melt-extruded tablets) were placed into a perforated pan-coater (HCT Mini 
HiCoater, Vector Corp, Cedar Rapids, IA), equipped with a peristaltic pump (505S 
Watson-Marlow, Wilmington, MA). The coating dispersions were kept under constant 
low shear stir during preparation and the film-coating process. The tablets were coated to 
completion, and were dried for 10 minutes at the processing temperature in the rotating 
pan. Some tablets were cured by placing them on open containers into ovens for the 
prescribed time. All tablets were stored in desiccators at 17% relative humidity until they 
were packaged.  
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3.2.3 Storage conditions  
 
For stability studies in supportive objective I and III, the tablets were packaged 
with one desiccant bag (One gram silica gel Minipax, Impak, Los Angeles, CA) into 
HDPE containers (MoldRite Plastics, Plattsburgh, NY), which were induction sealed 
(Compak Jr, Enercon, Menomonee Falls, WI) and placed into appropriate storage 
chambers. 
In supportive objective II and IV, tablets were filled into open containers and 
placed in storage chambers, which were maintained at a constant ambient temperature. 
The desiccant Drierite® (anhydrous calcium sulfate containing an indicator) equilibrated 
the low humidity chambers to 17±3.5% RH. For supportive objective II, saturated sodium 
chloride solution was used in storage chambers to create “high humidity” conditions at 
78±3.5% relative humidity. The relative humidity was measured in the chambers 
throughout the study by a Traceable humidity and temperature pen (Control Company, 
Friendswood, TX). 
 
3.2.4 Film Preparation 
 
Films containing 900 mg solids were prepared by weighing out and blending the 
components on wax paper, which were then dispersed in 20-35 milliliters of 200 proof 
ethanol, DI water, or mixtures thereof.  After stirring for at least 30 minutes under low 
shear until all components were dissolved, the solutions were cast into aluminum dishes 
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(Fisher Scientific, Hampton, NH) and were dried for 24 hours or until dry under a fume 
hood (alcohol based films) or in a 60 °C oven (water based films).  
 
3.2.5 Thermal analysis 
 
Differential scanning calorimetry (DSC) was used to determine the melting points 
of drugs in powder blends and modulated DCS (MDSC) was used to determine the glass 
transition temperature of polymers alone or in mixtures. A ceramic mortar and pestle was 
used to prepare powder mixtures and to crush melt extrudates. All powder blends were 
prepared in a ceramic mortar and pestle. Three to twenty milligram samples were 
analyzed in crimped aluminum pans (Kit 0219-0041 Perkin-Elmer Instruments, Norwalk, 
CT) on a calorimeter (Thermal Advantage Model 2920, TA Instruments, Newcastle, DE) 
equipped with Thermal Advantage Instrument Control Software for instrument control 
and Universal Analysis 2000 for data analysis. Ultra pure nitrogen was used as a purge 
gas at a flow rate of 150 mL/min.  
For supporting objective I, heating ranges were chosen to begin about 50°C below 
the expected glass transition temperatures of the blends and run to approximately 30°C 
after the end of the transition at a heating rate of 3°C/min with a temperature modulation 
of ±1°C every 30 seconds. DSC was used to investigate guaifenesin solubility in 
hydrophilic polymers using a heat-cool-heat cycle. The 1:1 mixtures were equilibrated at 
10°C, heated up to 110 °C at 5°C per minute, then cooled to 0°C at 10°C per minute, and 
heated up to 110 °C at 5°C per minute.  
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For supporting objective IV, DSC of powder samples determined the melting 
points of guaifenesin and diltiazem in binary powder blends and in the extrusion blend. 
The temperature ranged from 50 to 230°C at a heating rate of 10°/minute. MDSC 
determinations of blends containing guaifenesin, diltiazem hydrochloride and Eudragit® 
L100-55 were analyzed at a heating rate of 15°C/minute from 50 to 170°C, with a 
temperature amplitude of 0.5° every 40 seconds. 
 
3.2.6 Powder X-Ray Diffraction  
 
Powder x-ray diffraction was used to study the crystalline or amorphous state of 
drug and polymer in the powder blends and the extrudates. All powder samples were 
screened prior to analysis, and sample holders or glass slides were filled to a constant 
weight. Stored or freshly cut tablets were arranged on a glass slide, while some extrudates 
were ground prior to analysis. Films were cut and placed as flat as possible on the sample 
holder. The samples were scanned using a Phillips Vertical Scanning Diffractometer, 
Type 42273 (Phillips Electronic Instruments, Mahwah, NJ), employing CuKα radiation, 
operating at 40kV and 20-30 mA. The scan radius ran from 5° to 70° or 10° to 60° 
degrees, and the step size was 0.05° every 1.5 or 2 seconds (supporting objective I). The 
scan radius ranged from 10° to 60° degrees, and the step size was 0.05° every 4 seconds 
(supporting objective III). The scan radius ran from 10° to 40° degrees, and the step size 




3.2.7 Scanning Electron Microscopy and Energy-Dispersive Spectroscopy   
 
Scanning electron microscopy (SEM) was used to study the surface morphology 
of the extrudates, and to investigate the recrystallization processes on the surface of the 
hot-melt extruded tablets.  
To determine the onset of crystallization (supporting objective I), previously 
stored tablets were bisected and then either observed immediately or equilibrated at 
ambient conditions for predetermined time periods (5-30 minutes). Sputter-coating was 
performed at the end of the equilibration period. Samples were mounted on stubs with 
carbon tape (EMS, Fort Washington, PA) and dappled with silver adhesive as needed 
(503, EMS, Fort Washington, PA). Sputter coating was performed in a Ladd Benchtop 
Sputter Coater (Ladd Research, Winston, VT) at 2.5 kV and 20 mA for 75 sec under 
Argon with a gold/palladium mixture in a 60/40 ratio. The images were captured with an 
electron microscope (Phillips 515, Phillips Electronic Instruments, Mahwah, NJ) 
equipped with Semicaps 2000 software (Semicaps, San Jose, CA), operating at 15 kV and 
20 µA. The surface of the tablets was surveyed, and a representative area was chosen for 
the micrograph. 
For supporting objectives II-IV, all tablets were coated with a 15 nm thick 
platinum/palladium coating (80/20), applied by a Cressington Sputter Coater 208 HR 
(Watford, UK) equipped with a thickness controller MTM 20 at 2.5 kV, 20 mA under 
Argon.  For supporting objectives II and III, images were taken in field emission mode at 
5 kV using a Zeiss Supra 40VP electron microscope (Carl Zeiss SMT, Peabody, MA) 
equipped with a Gemini Column and SmartSEM software.  
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SEM imaging and EDS mapping for supporting objective IV were carried out 
using a LEO 1530 electron microscope (LEO Electron Microscopy, Thornwood, NY) 
equipped with a Gemini field emission column and a Gresham Sirius 10 detector (e2v 
scientific instruments, Woburn, UK) for EDS. SEM micrographs were captured at 10 kV 
using LEO-32 software.  EDS mapping of carbon, oxygen and chlorine present in the 
sample was carried out using EDS2006 software (IXRF systems, Houston, TX). Each 
sample was investigated in both cross-sections as well as longitudinal sections through 
the extrudate strand in at least 3 distinct locations to ensure that the scans were 
representative. 
 
3.2.8 Moisture Uptake of Tablets 
 
Moisture uptake of stored tablets was measured for supporting objective II by 
observing the mass loss on drying (LOD) of samples using a moisture-analyzing balance 
(AND MF-50 Moisture Analyzer, A&D Instruments, Abingdon, UK). Two gram samples 
were prepared by cutting the tablets into slices (thickness ca 0.2-0.5 mm), which were 
then arranged in a single layer in a pre-dried aluminum weighing pan. The percent loss on 
drying was recorded after heating the sample for 30 minutes at 110 °C. In addition to any 
moisture taken up during storage, formulations contained substances which partially 
volatilized under the test conditions, triethylcitrate and guaifenesin. To differentiate 
between the mass loss due to moisture and the mass loss due to other components, 
excipient powders, extrusion blends and tablets, all stored at 17% RH as well as 78% 
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relative humidity, were analyzed. The difference in the loss on drying results between 
tablets of the same formulation stored at either 78% or 17% RH was reported as the water 
uptake of the tablets.  
 
3.2.9 Mass Spectrometry (MS) 
 
Mass spectrometry was employed to identify the surface crystals in supporting 
objective II. The surfaces of stored tablets, which had developed surface crystallization, 
were scraped with a clean razor blade in several locations. The removed material was 
transferred to a capillary tube (Kimax-51, Kimble, Vineland, NJ) which was melted shut  
and analyzed on a Finnigan MAT TSQ 700 (ThermoFisher, Waltham, MA) using direct 
exposure probe desorption chemical ionization (DCI).   
 
3.2.10   In-Vitro Drug Release Testing 
 
Dissolution testing was performed to study the drug release properties of the 
guaifenesin tablets using USP 27 Apparatus 2 (Varian Industries, Inc. VK 7000, Palo 
Alto, CA) equipped with an auto sampler (Varian Industries, Inc. VK 8000, Palo Alto, 
CA).  Dissolution studies on melt-extruded tablets containing guaifenesin and 
recrystallization inhibitors were conducted via the basket method using USP apparatus 1, 
since the tablets swelled during the test, and the basket method showed less variability in 
the results than the paddle method.  Both dissolution tests were conducted at 37°C and 50 
48 
 
rpm in 900 mL 0.1 N hydrochloric acid for two hours, followed by eight hours in 900 mL 
0.05 M phosphate buffer pH 6.8 (n=6). At the end of each dissolution test, complete drug 
release was obtained by mixing the vessel contents with a homogenizer for 2 minutes to 
ensure total disintegration of the tablets. Samples were filtered through a 0.45 or 0.22 
micron nylon filter before HPLC analysis (Puradics 25NYL syringe filter and Puradics 
45NYL syringe filter; Whatman, Maidstone, UK) to remove insoluble excipients.  
 
In supporting objective IV, dissolution studies of guaifenesin tablets were 
conducted in 900 mL 0.05 M phosphate buffer pH 6.8 (n=3) at 37°C and 50 rpm for 8 
hours. Dissolution studies on melt-extruded tablets containing DIL and guaifenesin were 
conducted in 900 mL simulated gastric fluid without pepsin (n=3) at 37°C and 50 rpm for 
8 hours. At the end of each dissolution test, complete drug release was obtained by 
mixing the vessel contents with a homogenizer for one minute to ensure total 
disintegration of the tablets. The dissolution samples were filtered through a 0.22 micron 
nylon filter (Puradics 25NYL syringe filter, Whatman, Maidstone, UK) to remove 
insoluble excipients before quantifying the drug by UV testing. 
 
3.2.11 Drug Content Determination 
 
The drug content was determined to study the drug distribution in the extrudates. 
Thin sections of the extruded rods were accurately weighed and placed in volumetric 
flasks containing 100.0 mL of phosphate buffer pH 6.8 (n=3). After the sections had 
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dissolved, the medium was filtered through a 0.22 micron nylon filter (Puradics 25NYL 
syringe filter, Whatman, Maidstone, UK). The drug content of each sample was analyzed 
by UV testing as described in section 2.8. 
 
3.2.12 Assay for Crystalline Surface Guaifenesin 
 
Melt extruded tablets containing guaifenesin were assayed for surface crystallized 
drug substance using the procedure described in Figure 5.2.  Briefly, individual tablets 
were accurately weighed and a single tablet was placed into a large test tube (25x150 
mm) filled with either 3.0 or 5.0 mL of 0.1 N hydrochloric acid. The test tube was 
subjected to vortex mixing (SP vortex mixer, Baxter Diagnostic, Deerfield, IL) at a fixed 
agitation force for 5 seconds. Immediately after vortex mixing, the medium was decanted 
and filtered through a 0.22 micron nylon filter (Puradics 25NYL syringe filter, Whatman, 
Maidstone, UK). The filtered medium containing the dissolved guaifenesin from the 
tablet surface was analyzed by UV analysis. Residual liquid on the recovered tablets was 
blotted off and the tablets were dried at ambient conditions. The dimensions of dried 
tablets (height and diameter) were measured using calipers (Starrett, Athol, MA). Test 
conditions, including immersion time, vortex intensity, vessel size and dilution for the 





3.2.13 Sample Analysis 
 
Samples were analyzed for guaifenesin content using a Waters high performance 
liquid chromatography (HPLC) system with a photodiode array detector (Model 996) 
extracting 276 nm for guaifenesin (Waters, Milford, Ma).  An auto sampler (Waters 
Model 717plus) was used to inject 10 microliter.  The data were collected and integrated 
using Empower® Version 5.0 software (Waters).  The column used for guaifenesin 
analysis was an Alltech Versapack C18 10 micrometer, 250 x 4.1mm (Alltech, Deerfield, 
IL). The mobile phase consisted of water, methanol and glacial acetic acid in the volume 
ratio 600:400:15, respectively. The retention time of the guaifenesin was 3.1 minutes.   
Both mobile phase solvents were vacuum filtered through a 0.45 micron nylon membrane 
(0.45 micron nylon membrane filters by Whatman, Maidstone, GB) and degassed using a 
Waters In-Line Degasser AF. Linearity for guaifenesin was demonstrated from 2 to 80 
mg/microliter (R2 ≥ 0.997) and injection repeatability was 1% relative standard deviation 
for 6 injections.  
 
The drug content in samples from dissolution testing, drug content analysis and 
recrystallization testing was determined by UV analysis (supporting objectives II-IV). 
The guaifenesin content was quantified at 273 or 275 nm in 200 or 400 microliter 
samples by UV spectroscopy (µQuant UV Spectrometer equipped with KC 4 software for 
data analysis, BioTek Instruments, Inc, Winooski, VT). Linearity was established for 
drug concentrations between 8 and 200 ng/mL (R2=0.9968). Concentrations of 2 ng/mL 




DIL was analyzed at 230 nm using the same instrument.  For drug content analysis, 
50 microliter samples were diluted with 350 microliter of 0.05 M phosphate buffer pH 
6.8. Dissolution test samples were diluted with simulated gastric fluid without pepsin in a 
1 to 1 ratio. Linearity was established for drug concentrations between 10 and 200 
mg/mL (R2=0.9994).    
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The purpose of the study was to investigate the physical state of hot-melt extruded 
guaifenesin tablets containing either Acryl-EZE® or Eudragit L100-55® and to study the 
physicochemical factors influencing crystal growth of guaifenesin on the surface of the 
extrudates. The powder mixtures containing Acryl-EZE® were extruded on a single-
screw Randcastle Microtruder at 20 RPM and at temperatures of 90°C, 95°C, 110°C 
(zones 1,2,3, respectively) and 115°C (die), before being manually cut into tablets (250±5 
mg). Extrudates containing Eudragit L100-55®, TEC and guaifenesin were extruded at 
temperatures ranging from 60 to 115°C. Modulated differential calorimetry (DSC) was 
used to demonstrate the plasticizing effect of guaifenesin on Eudragit L100-55®. Powder 
x-ray diffraction (PXRD) showed that while the drug powder is crystalline, extrudates 
containing up to 25% drug exhibited an amorphous diffraction profile. Extrudates 
containing higher drug concentrations showed an amorphous profile with some 
crystalline peaks corresponding to guaifenesin, indicating that the limit of solubility of 
drug in the matrix had been exceeded. Scanning electron microscopy was used to 
demonstrate that drug crystallization was a surface phenomenon and dependent on the 
drug concentration. In-vitro dissolution testing showed no effect of surface crystallization 
of guaifenesin on drug release rates of extruded matrix tablets.  The influence of 
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hydrophilic polymeric additives including PVP K25, polycarbophil, PEG 3350, 
poloxamer 188 or poly(ethylene oxide) as crystal growth inhibitors was investigated at a 
level of 10% based on the drug content. The extent of crystal growth was reduced for all 
additives. Complete drug release in pH 6.8 phosphate buffer was prolonged from 4 hours 
in extrudates containing Acryl-EZE® and guaifenesin to 8 hours in extrudates containing 
Eudragit L100-55®, TEC and guaifenesin. Drug release in extrudates containing Eudragit 
L100-55® and guaifenesin was not affected by the presence of hydrophilic additives 
present at 10% based on the drug content. In-vitro drug release studies showed no 
significant change during storage for up to 6 months at 25°C/60% relative humidity and 




Hot-melt extrusion (HME) has been demonstrated to be a simple and continuous 
one-step process to prepare dosage forms such as tablets (Fukuda et al., 2006, Liu et al., 
2001), pellets (Christopher R. Young, 2005) and films (Crowley et al., 2004, Repka, 
2000) as well as intermediates that can be further processed by milling or cryogenic 
grinding to yield a powder to be used in compression or powder coating. Hot-melt 
extruded formulations consist of drug that is either dispersed or dissolved in one or more 
thermal carriers, resulting in a matrix system. Thermal lubricants such as talc and 
glycerol monostearate facilitate the movement of the formulation through the barrel of 
the unit. The processing temperatures should be sufficiently high to soften or melt the 
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thermal carrier and to allow mixing of the various components of the formulation. The 
residence times for blends in the extruder at elevated temperatures are short and usually 
in the range of 1.5 to 4 minutes. An extruded product typically displays excellent content 
uniformity due to the intense mixing and agitation in the barrel. 
 
While preformulation, processing and the stability of drug release during storage of 
hot-melt extruded dosage forms have been investigated, less attention has been paid to 
the physical stability of hot-melt extrudates. To characterize extruded formulations, it is 
important to know how the drug loading and the processing conditions influence drug 
recrystallization from the dosage form, and how these factors affect drug release. The 
crystallization of drug substances from the amorphous state has been a concern in freeze 
dried products and with drug-containing transdermal matrix systems.  Crystallization 
inhibition in these dosage forms as well as in hot-melt extrudates can be achieved by 
decreasing the amount of supersaturation driving the recrystallization or by interfering 
with the crystallization process. Many polymers, among them Eudragit RL PO, Eudragit 
E PO (Kotiyan and Vavia, 2001), polyvinyl pyrrolidone (PVP) (Yoshioka, 1995), and 
some low molecular weight compounds such as sodium chloride, boric acid and sodium 
tetraborate have been shown to inhibit recrystallization (Telang, 2003, Yoshinari et al., 
2003, Izutsu et al., 2004). Poly(ethylene oxide) was shown to reduce recrystallization of 
amorphous indomethacin in compression (Schmidt, 2004). Additives can interfere with 
crystal formation and growth when incorporated into the growing crystal face (Myerson 
and Jang, 1995), thereby stunting crystal growth and affecting crystal habit. It has been 
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proposed that intermolecular forces between the drug and the additive, such as hydrogen 
bonding, are responsible for this type of crystallization inhibition (Raghavan et al., 2001, 
Weuts et al., 2005). Drug concentration, processing conditions, storage time, humidity 
and temperature as well as additives have been found to affect recrystallization (van 
Laarhoven et al., 2002). Crystallization inhibition is very specific to the combination of 
drug and additive, and in some combinations additives were shown to promote 
crystallization rather than to inhibit crystal growth (Ma et al., 1996). Employing changes 
in processing, such as the rapid cooling of a melt or freeze drying without additives, 
usually will not provide long term physical stability because the crystalline forms are 
usually more thermodynamically stable, and the amorphous forms may, over time, revert 
back to the more stable crystalline form under ambient conditions. Since the degree of 
supersaturation is related to the crystallization of drug, reducing the drug loading could 
reduce drug recrystallization, but this may not be a viable option. 
  
Acryl-EZE® is a pre-formulated, dry enteric acrylic coating system for solid 
dosage forms and contains Eudragit® L100-55 plasticized with 4.8% triethyl citrate 
(TEC) along with talc and other components. Earlier work in our laboratories has 
highlighted the properties and applications of Acryl-EZE® as a thermal carrier in melt 
processing (Young et al., 2005), resulting in matrix formulations. The use of Acryl-
EZE® as a ready-made blend for melt extrusion is advantageous, as it can reduce 
formulation work while resulting in elegant extruded enteric dosage forms. During initial 
studies, the formation of crystals on the tablet surface was observed. We decided to 
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investigate this phenomenon as it will impact the long-term physical stability of melt-
extruded dosage forms containing Acryl-EZE®. Crystal growth on the tablet surface 
presents a change in the physical form of the drug. This is problematic for several 
reasons. Crystals can shear from the tablet, resulting in a lower dose of the active. 
Depending on the solubility of the drug, the dissolution properties of the dosage form 
may change as the tablet is enveloped in a layer of drug crystals which may change the 
interaction of the matrix with the medium. To simplify the present investigations, some 
studies were performed in melt extrudates containing only Eudragit L100-55®, rather 
than the entire blend. Guaifenesin forms needle-shaped crystals from solutions or melts 
and has a melting point of about 79°C. It was chosen as the model drug since it melted 
under the processing conditions and is very water-soluble. The goal of this study was to 
investigate the factors influencing the growth of guaifenesin crystals on hot-melt 
extruded matrix tablets containing either Acryl-EZE® or Eudragit L100-55®. This study 
investigated the effects of guaifenesin recrystallization on the surface of melt-extruded 
tablets on drug release properties. The influence of hydrophilic polymeric additives on 
crystal growth inhibition and on drug release properties was also investigated. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
 
Guaifenesin was purchased from Spectrum (Gardena, CA), and was used as 
model drug. Acryl-EZE® was donated by Colorcon (West Point, PA). Eudragit L100-
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55® was given by Röhm GmbH (Darmstadt, Germany). Triethyl citrate (TEC) was 
kindly donated by Morflex (Greensboro, NC). Talc (Imperial 500, USP) was provided by 
Luzenac America (Centennial, CO). Hydrophilic polymers including Kollidon 25 (PVP 
K25), Pluracol E 3350 (PEG 3350) and Pluronic F68 (Poloxamer 188), were all donated 
by BASF (Florham Park, NJ). Noveon AA1 (Polycarbophil) was donated by Noveon 
(Cleveland, OH), and Polyox WSR 303 (Poly (ethylene Oxide)) was donated by Dow 
Chemical (Midland, MI). Ethanol (200 proof) was purchased from AAPER Alcohol and 
Chemical (Shelbyville, KY). 
 
4.2.2 Tablet Preparation 
 
Tablets were prepared by hot-melt extrusion of the powder blends, followed by 
manual cutting of the extrudate strand. The formulations are presented in Table 4.1. 
Premixed powder blends were fed into a single screw Randcastle extruder (Randcastle 
Microtruder Model RCP-0750, Cedar Grove, NY) equipped with a Nitralloy 135M 
screw (3:1 compression ratio with flight configuration containing feed, compression and 
mixing sections). The round die had a diameter of 6 mm. The three heating zones and the 
die were equilibrated at the processing temperatures for 30 minutes before extrusion. The 
extrudates were allowed to cool at room temperature for 24 hours before manually 
cutting tablets weighing 250±5 mg. For stability studies, the tablets were packaged with 
one desiccant bag (One gram silica gel Minipax, Impak, Los Angeles, CA) into HDPE 
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containers (MoldRite Plastics, Plattsburgh, NY), which were induction sealed (Compak 
Jr, Enercon, Menomonee Falls, WI) and placed into appropriate storage chambers. 
 
  The processing temperatures chosen for extrudates containing Acryl-EZE® and 
guaifenesin were 90°C, 95°C, 110°C (zones 1, 2, 3, respectively) and 115°C (die). These 
temperatures were optimized in earlier studies investigating the suitability of Acryl-
EZE® for hot-melt extrusion. Melt extrudates containing Eudragit L100-55® and 
guaifenesin were extruded at lower temperatures as shown in Table 4.3. Processing 
conditions were adjusted to obtain an acceptable extruded product at an adequate 
extrusion speed. Two in-process parameters, including the barrel pressure and machine 
current, were used to monitor the processability of the blends. The barrel pressure is the 
pressure exerted by the molten formulation inside the barrel; the machine current is the 
energy required to maintain the screw at a constant speed. The processing conditions for 
extrudates containing Acryl-EZE® and Eudragit L100-55® are shown in Table 4.2 and in 
Table 4.3, respectively.   
4.2.3 Film Preparation 
 
Films containing 900 mg solids were prepared by weighing out and blending the 
components on wax paper, which were then dispersed in 20-35 milliliters of 200 proof 
ethanol, DI water, or mixtures thereof.  After stirring for at least 30 minutes under low 
shear until all components were dissolved, the solutions were cast into aluminum dishes 
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(Fisher Scientific, Hampton, NH) and were dried for 24 hours or until dry under a fume 
hood (alcohol based films) or in a 60 °C oven (water based films).  
 
4.2.4 Glass Transition Temperature (Tg) Determination 
 
Modulated differential scanning calorimetry (MDSC) was used to characterize the 
thermal properties of the extrusion blends and extrudates. Power samples were prepared 
for mDSC by screening. Extrudates were thinly sliced and then crushed in a ceramic 
mortar and pestle. After weighing, the samples (10±5 mg) were placed into aluminum 
pans (Kit 0219-0041 Perkin-Elmer Instruments, Norwalk, CT), fitted with a lid, and 
crimped. The analysis was conducted on a Thermal Advantage Model 2920 from TA 
Instruments (Newcastle, DE) equipped with Thermal Advantage Instrument Control 
Software and Universal Analysis 2000. Ultra pure nitrogen was used as a purge gas at a 
flow rate of 150 mL/min. The scan proceeded at a heating rate of 3°C/min with a 
temperature modulation of ±1°C every 30 seconds. The heating ranges were chosen to 
begin about 50°C below the expected glass transition temperatures of the blends and run 
to approximately 30°C after the end of the transition. Differential scanning calorimetry of 
physical blends of guaifenesin and polymers was performed on the same instrument on a 
heat-cool-heat cycle. The 1 to 1 mixtures were equilibrated at 10 °C, heated up to 110 °C 




4.2.5 Powder X-Ray Diffraction  
 
Powder x-ray diffraction was used to study the crystalline or amorphous state of 
drug and polymer in the powder blends and the extrudates. All powder samples were 
screened prior to analysis, and deep bed sample holders were filled to a constant weight. 
Stored or freshly cut tablets (250±5mg) were arranged on a glass slide, while some 
extrudates were ground prior to analysis. Films were cut and placed as flat as possible on 
the sample holder. The samples were scanned using a Phillips Vertical Scanning 
Diffractometer, Type 42273, employing CuKα radiation, operating at 40kV and 20mA. 
The scan radius ran from 5° to 70° or 10° to 60° degrees, and the step size was 0.05° 
every 1.5 or 2 seconds. 
 
4.2.6 Scanning Electron Microscopy 
 
Scanning electron microscopy (SEM) was used to study the surface morphology 
of the extrudates, and to investigate the recrystallization processes on the surface of the 
hot-melt extruded tablets. To determine the onset of crystallization, previously stored 
tablets were bisected and then either observed immediately or equilibrated at ambient 
conditions for predetermined time periods (5-30 minutes). Sputter-coating was performed 
at the end of the equilibration period. Samples were mounted on stubs with carbon tape 
(EMS, Fort Washington, PA) and dappled with silver adhesive (503, EMS, Fort 
Washington, PA). Sputter coating was performed in a Ladd Benchtop Sputter Coater 
(Ladd Research, Winston, VT) at 2.5 kV and 20 mA for 75 sec under Argon with a 
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gold/palladium mixture in a 60/40 ratio. The images were captured with a Phillips 515 
SEM equipped with Semicaps 2000 software operating at 15 kV and 20 µA. The surface 
of the tablets was surveyed, and a representative area was chosen for the micrograph. 
 
4.2.7 In-Vitro Drug Release Testing 
 
Dissolution testing was performed to study the drug release properties of the 
guaifenesin tablets using USP 27 Apparatus 2 (Varian Industries, Inc. VK 7000, Palo 
Alto, CA) equipped with an auto sampler (Varian Industries, Inc. VK 8000, Palo Alto, 
CA).  Dissolution studies on melt-extruded tablets containing guaifenesin and 
recrystallization inhibitors were conducted via the basket method using USP apparatus 1, 
since the tablets swelled during the test, and the basket method showed less variability in 
the results than the paddle method.  Both dissolution tests were conducted at 37°C and 50 
rpm in 900 mL 0.1 N HCl for two hours, followed by eight hours in 900 mL 0.05 M 
phosphate buffer pH 6.8 (n=6). At the end of each dissolution test, complete drug release 
was obtained by mixing the vessel contents with a homogenizer for 2 minutes to ensure 
total disintegration of the tablets. Samples were filtered through a 0.45 or 0.22 micron 
nylon filter before HPLC analysis (Puradics 25NYL syringe filter, Lot Number R180 and 
Puradics 45NYL syringe filter, Lot Number S594; Whatman, Maidstone, GB) to remove 
insoluble excipients. The samples were filtered through a 0.45 micron nylon filter, 




4.2.8 Dissolution Sample Analysis 
 
Samples were analyzed for guaifenesin content using a Waters high performance 
liquid chromatography (HPLC) system with a photodiode array detector (Model 996) 
extracting 276 nm for guaifenesin (Waters, Milford, Ma).  An auto sampler (Waters 
Model 717plus) was used to inject 10 µL.  The data were collected and integrated using 
Empower® Version 5.0 software (Waters).  The column used for guaifenesin analysis 
was an Alltech Versapack C18 10 µm, 250 x 4.1mm (Alltech, Deerfield, IL). The mobile 
phase consisted of water, methanol and glacial acetic acid in the volume ratio 
600:400:15, respectively. The retention time of the guaifenesin was 3.1 minutes.   Both 
mobile phase solvents were vacuum filtered through a 0.45 µm nylon membrane (0.45 
µm nylon membrane filters by Whatman, Maidstone, GB) and degassed using a Waters 
In-Line Degasser AF. Linearity for guaifenesin was demonstrated from 2 to 80 mg/µL 
(R2 ≥ 0.997) and injection repeatability was 1% relative standard deviation for 6 
injections.  
 
4.3 RESULTS AND DISCUSSION 
 
The processing temperature of a melt extrusion process is selected based on the 
melting or softening temperature of the thermal carrier or the extrusion blend. The drug 
may or may not melt under these conditions. Guaifenesin has a melting point of 79°C, 
and formed a melt during extrusion at the processing conditions used. Mani et al reported 
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on the properties and solubilities of guaifenesin (Mani et al., 2003). An extrusion blend 
that is well plasticized and contains thermal lubricants can be extruded at lower 
temperatures and pressures, and such a blend will extrude faster and result in a better 
product. To study the effect of the molten drug on the processing conditions, extrudates 
containing Acryl-EZE® and guaifenesin were prepared. These blends flowed well in the 
hopper, extruded fast, and yielded smooth, regular extrudates without die swell. The 
barrel pressure and the torque decreased with higher guaifenesin content.  
 
To distinguish between the lubricant properties of the guaifenesin melt and a 
plasticizing effect of the drug on the polymer, the glass transition temperatures of melt 
extrudates containing 5%, 10%, 15% and 20% of guaifenesin in Eudragit L100-55® were 
determined, and a concentration-dependent decrease was found (Figure 4.1). The glass 
transition temperature of Eudragit L100-55® decreased from 104.4°C without any 
guaifenesin to 51°C with 20% drug. Extrudates containing Eudragit L100-55® were 
employed for this purpose instead of Acryl-EZE®-containing product as Acryl-EZE® 
contains of other components which complicate the determination of the glass transition 
temperature. The sharp decrease in the glass transition temperature with increasing 
guaifenesin content indicated that the favorable processing conditions were mainly due to 
the plasticizing effect of the drug on the polymer. In previous studies, solid state 
compounds such as ibuprofen (Wu and McGinity, 1999) and methylparaben (Wu and 
McGinity, 2003) were shown to plasticize acrylic polymers during processing, 
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demonstrating that actives and excipients can be used as non-traditional plasticizers in 
hot-melt formulations.  
 
The effect of hot-melt extrusion on the aggregate state of guaifenesin was 
investigated by powder x-ray diffraction. Eudragit L100-55® rather than Acryl-EZE®-
containing formulations were employed because crystalline components in Acryl-EZE® 
obscured small changes in the amorphous part of the spectrum. As seen in Figure 4.2, the 
thermal carrier Eudragit L100-55® was amorphous as the powder x-ray diffraction 
profiles show an amorphous profile without crystalline peaks. The unprocessed 
guaifenesin powder was crystalline, and the physical mixture of guaifenesin with 
Eudragit L100-55® exhibited partial crystallinity, showing peaks corresponding to 
guaifenesin, but at lower intensities. The powder x-ray diffraction profiles of ground 
extrudates containing 25%, 37.5% and 50% guaifenesin in Eudragit L100-55® were 
similar to the amorphous profile exhibited by the pure polymer (Figure 4.3). Crystalline 
peaks corresponding to guaifenesin started to appear in extrudates containing higher 
concentrations of drug (37%, 50%). These results demonstrated that there was an upper 
limit to the amount of drug that could dissolve in the molten polymer matrix and remain 
in an amorphous state as a solid solution in the extrudate on cooling and storage. 
 
Scanning electron microscopy of tablets stored for 1 month at 25°C and 60% 
relative humidity showed that the polymeric surface was obscured by crystals (Figure 
4.4). To determine the onset time of crystallization, previously stored tablets containing 
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Acryl-EZE® (Figure 4.5) or Eudragit L100-55® (Figure 4.6) with a guaifenesin content 
of 37.5% were bisected and then either observed immediately, or stored at ambient 
conditions for predetermined time periods. The formation of crystals was observed over 
30 minutes. No crystals were observed on the newly exposed matrix surface of tablets 
(Figure 4.5 (a) and Figure 4.6 (a)). SEM micrographs of the tablets which were sectioned 
and exposed to the environment 15 minutes (Figure 4.5 (b) and Figure 4.6 (b)) or 30 
minutes (Figure 4.5 (c) and Figure 4.6 (c)) before observation showed crystal growth for 
both thermal binders. Since no crystals were present when a new cut was first made, 
guaifenesin recrystallization on both Acryl-EZE®- and Eudragit L100-55®-containing 
extrudates was demonstrated to be a surface phenomenon which only occurred on the 
outside faces of the tablets. A possible explanation for these results is that the matrix 
exerted a restraining pressure large enough to prevent internal crystal growth, as the 
growing crystals would have to displace the matrix to accommodate their growth. This 
phenomenon was recently discussed by other researchers (Chatterji, 2005).  
 
SEM also demonstrated dependence of crystal growth on the drug concentration 
(Figure 4.7). Tablets containing higher guaifenesin levels were observed to have a higher 
level of drug recrystallization after storage for the same time period. SEM micrographs 
for Figure 4.7 a-c were taken under the same magnification (x101). The concentration-
dependent drug recrystallization indicated that the drug solubility in the polymeric matrix 
had been exceeded. Higher drug loading resulted in a higher degree of supersaturation in 
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the matrix, causing recrystallization on the surface of the tablet when equilibrated at 
ambient temperatures.  
 
The influence of surface crystallization of guaifenesin on the in-vitro dissolution 
properties of both freshly extruded and aged extrudates was investigated. For initial 
samples, guaifenesin content had no influence on the drug release rate as seen in Figure 
4.8. Eudragit L100-55® is an enteric polymer that starts to dissolve above pH 5.5. In 0.1 
N hydrochloric acid, the polymer matrix remained intact although more than 10% drug 
was released after 2 hours. When the pH of the media was changed to phosphate buffer 
(pH 6.8), the polymer started to dissolve. For extrudates containing Acryl-EZE® and 
either 15%, 20% or 25% guaifenesin, complete drug release was achieved after 4 hours in 
phosphate buffer pH 6.8. The results in Figure 4.9 show that the drug release rate did not 
change significantly for tablets stored for either 3 weeks or 6 months at 25°C and 60% 
relative humidity as well as at 40°C and 75% relative humidity. This can be explained 
from the observation that guaifenesin crystals were only present on the tablet surface and 
the total amount of recrystallized drug was small compared to the amount in an 
amorphous state inside the matrix. Guaifenesin is highly soluble in both the amorphous 
and in the crystalline form. The drug release rates of extruded matrix tablets stored in 
induction-sealed containers showed no change and the performance of melt extruded 
tablets was not influenced by the formation of drug crystals on the tablet surface. Melt-
extruded products tend to show good long term stability (Hülsmann et al., 2001). Long 
term stability can be influenced by the storage conditions. Remon and coworkers found 
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that drug release can be increased after storage under high humidity conditions since the 
molecular mobility within the matrix was increased (De Brabander et al., 2003).  
 
In order to test the ability of five hydrophilic polymers to act as crystallization 
inhibitors, PVP K25, PEG 3350, poloxamer 188, poly (ethylene oxide) or polycarbophil 
were incorporated into the formulation (Table 4.1). Each blend contained one of the 
polymers and 25% guaifenesin in Eudragit L100-55®. The additives were employed at a 
level of 10%, based on the amount of guaifenesin in the formulation and were 
incorporated into the initial powder blend for extrusion before processing. These 
additives were selected either because they are well-known solubilizers (PVP), because 
guaifenesin was known to have solubility in similar lower molecular weight polymers 
(Mani et al., 2003) (PEG, poloxamer 188), or because of structural similarity to these 
polymers (polycarbophil, poly (ethylene oxide)). DSC performed on the physical 
mixtures of drug and each of the polymers revealed that in the second heating cycle of the 
heat-cool-heat program the heat of fusion of guaifenesin was absent or reduced for all 
polymers. This indicated that the drug was solubilized by the polymer in the first heating 
cycle, and either did not recrystallize on cooling or a reduced amount recrystallized.  
Therefore, the drug exhibited either no or a reduced peak for the heat of fusion in the 
second heating run, indicating at least some solubility of the drug in the polymers (data 
not shown). The use of a DSC method to select crystallization inhibitors was used by 




Scanning electron micrographs were taken soon after extrusion (Figure 4.10) and 
after 4 weeks of storage at 25°C and 60% relative humidity (Figure 4.11). The extrudates 
containing PEG 3350 showed crystal growth under high magnifications soon after 
extrusion and was similar to the extrudates without additive. After four weeks of storage, 
surface crystallization had occurred in all formulations and the extent of crystallization 
observed on the tablets with each hydrophilic additive was less than on tablets without 
any additives. Extrudates containing polycarbophil and PVP K25 exhibited reduced drug 
recrystallization compared to the other formulations containing an additive after 4 weeks 
of storage (Figure 4.11 a and d, respectively). None of the additives changed the crystal 
habit of the re-crystallized guaifenesin. This indicated that the crystallization inhibitors 
did not interfere with the growing crystal face. Together with the DSC results, the 
decrease in crystallization of the API can thus result from the increased solubility of the 
guaifenesin in the matrix containing both the acrylic polymer and the hydrophilic carrier. 
 
Extrudates containing Eudragit L100-55® released 100% of drug after 
approximately 8 hours in pH 6.8 phosphate buffer (Figure 4.12), as opposed to extrudates 
containing Acryl-EZE® and guaifenesin, which showed complete drug release after 4 
hours in pH 6.8 phosphate buffer (Figure 4.9). In extrudates containing Eudragit L100-
55® and guaifenesin, the presence of additives had no effect on the in-vitro drug release 
rates, and release properties of all extrudates were very similar. The difference in the 
release rates was due to the presence of other excipients present in Acryl-EZE®, which 
accelerate the break-up of the matrix, and thus speed up drug release. In extrudates 
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consisting of Eudragit L100-55®, TEC and guaifenesin, the drug release is due only to 
the dissolution of the polymer, which slowes the drug release. All hydrophilic additives 
tested were water-swellable polymers, whose hydration and erosion is a function of 
molecular weight. The melt-extruded tablets containing guaifenesin, Eudragit L100-55® 
and each of the hydrophilic additives swelled during dissolution testing. Formulations not 
containing the hydrophilic additives did not swell during dissolution testing. Drug release 
in formulations containing the hydrophilic additives was thus a function of the pH-
depended solubility of Eudragit L100-55® and the swelling/erosion caused by the 
hydrophilic additive. Due to the low levels of hydrophilic additive, the drug release rates 
were not affected.  The release rate did not change following four weeks of storage at 






Acryl-EZE® and Eudragit L100-55® were successfully extruded with guaifenesin 
as the model drug and guaifenesin had a plasticizing effect on the acrylic polymer. 
Preliminary results demonstrated that guaifenesin formed a solid solution in the acrylic 
polymer during processing and that at a 25% drug loading the saturation solubility of the 
guaifenesin in the Eudragit L100-55® was exceeded after the extrudate was cooled to 
ambient conditions, resulting in crystal formation at the surface of the tablet. The addition 
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of hydrophilic polymers to the matrix reduced the onset and the extent of drug 
recrystallization. Future studies will further address the solubility of guaifenesin in 
hydrophilic additives and the role of other formulation components on guaifenesin 
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15 255 - 45 - - 
20 240 - 60 - - 
Guaifenesin in 
Acryl-EZE® 
25 225 - 75 - - 
0 - 300 0 - - 
5 - 285 15 - - 
10 - 270 30 - - 
15 - 255 45 - - 
20 - 240 60 - - 
25 - 231.1 57.8 11.1 - 
37.5 - 210.8 79.1 10.1 - 
50 - 193.8 96.91 9.3 - 
Guaifenesin in 
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Model Drug % Model Drug Barrel Pressure  






Guaifenesin 15 0.4 234 90-95-110-115 
 20 0.2 157 90-95-110-115 
 25 0.2 124 90-95-110-115 
            




Model Drug % Model Drug Barrel Pressure  
(PSI x 1000) 





Guaifenesin 25 1.0 312 70-85-90-95 
 37.5 0.8 335 60-80-80-90 
 50 0.6 325 65-75-80-85 
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Figure 4.2 Powder x-ray diffraction profiles of guaifenesin, Eudragit L100-55®, and 
their physical mixture.  
 
Scan Range 5 to 70 degrees, Step size 0.05 degrees, Scan Speed 0.05 degrees/1.0 
second.  
 
(a) Eudragit L100-55® (powder), (b) Physical mixture 25% guaifenesin in Eudragit 

















Figure 4.3 Powder x-ray diffraction profiles of melt-extruded tablets containing 
Eudragit L100-55® and guaifenesin soon after extrusion.  
 
Scan Range 5 to 70 degrees, Step size 0.05 degrees, Scan Speed 0.05 degrees/1.0 
second.  
 












  (a) 
 (b)  
 
Figure 4.4 SEM micrographs of the surface of a hot-melt extruded tablet containing 
62.5% Eudragit L100-55® and 37.5% guaifenesin (based on total weight)  
 







  (a) 
 (b) 
 (c) 
Figure 4.5 SEM micrographs of hot-melt extruded tablets containing Acryl-EZE® 
and 37.5% guaifenesin.  







Figure 4.6 SEM micrographs of hot-melt extruded tablets containing Eudragit 
L100-55® and 37.5% guaifenesin.  







Figure 4.7 Influence of drug concentration on surface crystallization (storage 
25ºC/60% RH). SEM of hot-melt extrudate containing Eudragit L100-55® and 
various concentrations of guaifenesin.  































Figure 4.8 Influence of guaifenesin content on the dissolution rate from tablets 
containing Acryl-EZE®.  
 
Paddle, 900 mL, 37±0.5°C, 50 rpm, 2 hours 0.1N HCl, 8 hours pH 6.8 phosphate 
buffer, n=6.   
 

































    
Figure 4.9 Influence of storage for 3 weeks and 6 months on the dissolution rate of 
guaifenesin from melt-extruded tablets containing 25% guaifenesin and 75% Acryl-
EZE®.  
 
Paddle, 900 mL, 37±0.5°C, 50 rpm, 2 hours 0.1N HCl, 8 hours pH 6.8 phosphate 
buffer, n=6. 
 
 ♦ Initial (T=0);  
∆ T=3 weeks, storage 25°C/60% RH;  
X T=3 weeks, storage 40°C/75% RH;  
□ T=6 months, storage 25°C/60% RH;  







 (a) PVP K25 
  (b) PEG 3350 
 (c) Poloxamer 188 
 




 (d) Polycarbophil 
 (e) Poly(ethylene oxide) 
 
 
Figure 4.10 SEM micrographs of melt-extruded guaifenesin tablets containing 
Eudragit L100-55® and 25% guaifenesin with 10% crystallization inhibitor, based 
on the amount of drug. 
 
Soon after extrusion. 
 
(a) PVP K25 
(b) PEG 3350 
(c) Poloxamer 188 
(d) polycarbophil 




 (a) PVP K25 
 (b) PEG 3350 
 (c) Poloxamer 188 
(continued, including legend, on next page) 
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 (d) Polycarbophil 
 (e) Poly(ethylene oxide) 
 
 
Figure 4.11 SEM of melt-extruded guaifenesin tablets containing Eudragit L100-
55® with 10% crystallization inhibitor, based on the amount of drug.  
 
After 4 weeks of storage at 25°C/60% relative humidity. 
 
(a) PVP K25 
(b) PEG 3350 
(c) Poloxamer 188 
(d) Polycarbophil 
































Figure 4.12 Influence of 10% crystallization inhibitor (based on drug content)  on 
the dissolution of guaifenesin from tablets containing 25% guaifenesin and Eudragit 
L100-55®.  
 
Soon after extrusion.  
 
Basket, 900 mL, 37±0.5°C, 50 rpm, 2 hours 0.1N HCl, 8 hours pH 6.8 phosphate 
buffer, n=6.  
   
       Polycarbophil 
 X   PEG 3350 
 O   Poloxamer 188 
    PVP K25 
 -    No additive, 

































Figure 4.13 Influence of 10% crystallization inhibitor (based on drug content) on 
the dissolution of guaifenesin from tablets containing 25% guaifenesin and Eudragit 
L100-55®.  
 
After 3 weeks of storage at 25°C/60% relative humidity.  
 




X   PEG 3350 
O   Poloxamer 188 
   PVP K25 
-    No additive,  





Chapter 5: The Influence of Heterogeneous Nucleation on the Surface 
Crystallization of Guaifenesin from Melt Extrudates Containing 




This study investigated the influence of heterogeneous crystallization due to 
humidity conditions in storage and talc as a formulation component on the amount of 
guaifenesin recrystallizing on the surface of melt-extruded matrix tablets. Tablets 
consisted of the model drug guaifenesin in a matrix of either Acryl-EZE® or Eudragit® 
L100-55 and either no talc, 25% or 50% talc. The guaifenesin-to-polymer ratio was held 
constant in all formulations. After processing, the hot-melt extruded matrix tablets were 
supersaturated with amorphous guaifenesin. The drug supersaturation in the polymer 
resulted in the development of guaifenesin drug crystals on exposed surfaces of the tablet 
upon storage. A quantitative test was developed to assay for surface guaifenesin, which 
was based on a 5-second immersion and intense movement of a tablet in a medium able 
to dissolve guaifenesin, but not the matrix. In tablets with a drug-to-polymer ratio of 
19:81, only talc-containing tablets showed crystal growth after 4 days. The presence of 
talc increased the amount of surface crystallization. In tablets without talc (drug-to-
polymer ratio of 37.5: 62.5), 0.15±0.02% of the total guaifenesin dose recrystallized 
within 15 days of storage at 17% RH. In tablets containing 25% or 50% talc, 0.37±0.05% 
or 0.37±0.02%, respectively, of the total guaifenesin dose recrystallized under identical 
storage conditions. The effect of talc was not concentration-depended, since the talc 
levels used in this study exceeded the critical nucleant concentration. Additional non-
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melting components did not have an additive effect on surface crystal growth, as 
demonstrated on Acryl-EZE® tablets with an identical drug to polymer ratio, in which 
0.26±0.037% of the total guaifenesin dose recrystallized after 15 days storage at 17% 
RH. High humidity during storage increased guaifenesin crystallization, but moisture 
uptake of tablets did not correlate with increased drug recrystallization. Storage at 78% 
relative humidity increased guaifenesin surface crystallization to 0.43±0.14% of total 
drug dose, up from 0.15±0.02% in tablets stored for the same duration at 17% RH 
(Eudragit® L100-55 matrix tablets without talc). Other tablets were stored at 17% 
relative humidity, and then moved to 78% relative humidity for 3 days before being 
returned to their previous low RH storage conditions. Recrystallization levels quickly 
increased during the high RH interval, and did not return to previous levels. When 
storage at 78% RH was interrupted by 3 days of low RH (17%), surface crystallization 
levels remained constant. Once nucleation was induced by atmospheric moisture, crystals 
remained on the tablet surface regardless of relative humidity conditions thereafter. 
Storage of melt-extruded dosage forms supersaturated with amorphous drug at high 
humidity and the addition of talc to the formulation was shown to induce and increase 




Hot-melt extrusion (1, 2) has been employed to incorporate drugs into polymeric 
matrices (3-5). This process was shown to convert crystalline drugs into the amorphous 
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state (6-8). Drugs in the amorphous state generally exhibit higher aqueous dissolution 
rates (9) and enhanced in-vivo bioavailability (10). During hot-melt extrusion, the drug 
powder, the matrix-forming polymer and other excipients are heated for a short period of 
time. The matrix former will soften or melt and the other components will be dispersed in 
the melt as they move through the barrel of the extruder. Depending on their melting 
point and solubility in the matrix, formulation components can be dissolved or dispersed 
in the polymeric carrier. Formulation components will be trapped in the hardening matrix 
as the extrudate cools. Hot-melt extruded products usually demonstrate good content 
uniformity (11) due to intense mixing during processing.  
 
The amorphous state of a drug is thermodynamically unstable compared to 
crystalline forms. Recrystallization from the amorphous state compromises the essential 
quality of the dosage form, and has been reported for several drugs (12, 13). Tablet 
properties such as disintegration time and dissolution performance depend on the 
physical state of the drug and will be negatively affected by recrystallization. 
Furthermore, pure drug crystals located on the tablet surface can shear off, and thus 
diminish the total dose of the drug.  
 
In a previous study, we identified crystal growth as a sign of a physical instability 
of the matrix, resulting from supersaturation of guaifenesin in the polymer (14). Figure 
5.1 illustrates the problem and depicts the changes in the state of guaifenesin during melt 
extrusion. Guaifenesin melts during processing, since its melting point lies below the 
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extrusion temperature. The solubility of guaifenesin decreases at lower temperatures, 
consequently the matrix polymer can solubilize more guaifenesin at the higher extrusion 
temperatures than in the cooled extrudate, which results in a matrix supersaturated with 
guaifenesin, if the matrix contains more then 20% drug (15). Recrystallization occurred 
quickly. Within 15 minutes, guaifenesin crystals developed on tablets with a guaifenesin-
to-polymer ratio of 37.5 to 62.5 at room temperature (14). The same study demonstrated 
that crystals only developed on exposed surfaces of the extrudate. Our initial attempt to 
inhibit this crystal growth focused on enhancing the solubility of the drug in the matrix. 
The addition of selected hydrophilic polymers with higher solubility for guaifenesin 
decreased the supersaturation of the drug in the polymer, and hence reduced surface 
crystallization (14). 
 
While the supersaturation of the drug in the tablet is the driving force for 
crystallization (16), other factors such as formulation composition and storage conditions 
can influence the onset and extent of crystallization. Formulation components can hinder 
or accelerate crystal growth (17), and change the crystal habit (18). Talc is a common 
filler material, and has been reported to affect the crystallization of matrix polymers (19, 
20). An earlier film study (15), demonstrated a similar effect on guaifenesin for the 
present system.  Storage conditions, mainly temperature (21-23) and humidity (24-29) 




Formulation composition and storage conditions influence recrystallization by 
influencing the formation of nuclei which then grow into crystals. A supersaturated state 
can be sufficient for nucleation to occur. Such a spontaneous process is called 
homogeneous nucleation, since it is induced without the participation of other particles 
and is due only to the supersaturation of the nucleating species. This is considered a rare 
case due to the ubiquitous prevalence of impurities. In contrast, heterogeneous nucleation 
occurs when other particles or equipment surfaces induce nuclei formation at lower 
supersaturation levels or at lower supercoolings than observed in homogeneous 
nucleation. Thus, heterogeneous nucleation can induce and accelerate drug 
recrystallization from the amorphous state.  
 
Acryl-EZE® is a commercially available powder blend that is generally used for 
aqueous film-coating. It contains the pre-plasticized, enteric acrylic polymer Eudragit® 
L100-55 as well as non-melting components such as talc and titanium dioxide. In 
previous investigations (30), we reported that Acryl-EZE® may be readily processed by 
hot-melt extrusion, does not undergo die-swell, and yields extrudates with smooth 
surfaces. It was used in this study as an extrusion blend containing several non-melting 
components. 
 
The objectives of this study were threefold: to quantify the influence of talc on the 
recrystallization of guaifenesin from hot-melt extruded acrylic matrix tablets; to measure 
the impact of constant as well as cycling storage relative humidity on the recrystallization 
95 
 
of guaifenesin from tablets containing different levels of non-melting components, and 
finally, to investigate if the composition of the crystalline material on the tablet surface 
was influenced by talc and relative humidity.   
 
5.2 MATERIALS AND METHODS 
5.2.1 Materials 
Guaifenesin was purchased from Spectrum (Gardena, CA), and was used as the 
model drug. Acryl-EZE® was donated by Colorcon (West Point, PA). Eudragit® L100-
55 was provided by Evonik Degussa (Piscataway, NJ, particle size 95% below 250 
micron). Triethyl citrate (TEC) was kindly donated by Vertellus (Greensboro, NC). The 
talc employed in the study (Imperial 500 USP, particle size 4.5 micron) was a gift from 
Luzenac (Centennial, CO). Drierite (Hammond, Xenia, OH) and sodium chloride, ACS 
reagent (Sigma-Aldrich, St. Louis, MO) were purchased.   
 
5.2.2 Tablet Preparation 
Tablets were prepared by hot-melt extrusion of the powder blends, followed by 
manual cutting of the extrudate strand. The formulations are presented in Table 5.1, and 
component functions are listed in Table 5.2. Premixed powder blends were fed into a 
single-screw Randcastle extruder (Randcastle Microtruder Model RCP-0750, Cedar 
Grove, NY) equipped with a Nitralloy 135M screw (3:1 compression ratio with flight 
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configuration containing feed, compression and mixing sections). The round die had a 
diameter of 6 mm. The three heating zones and the die were equilibrated at the processing 
temperatures for 40 minutes before extrusion. The processing temperatures chosen for all 
extrudates were 65°C, 75°C, 85°C (barrel heating zones 1, 2, 3, respectively) and 85°C 
(extruder die).  
5.2.3 Storage conditions 
Tablets were filled into open containers and placed in storage chambers, which 
were maintained at 24°C. The desiccant Drierite® (anhydrous calcium sulfate containing 
an indicator) equilibrated the low humidity chambers to 17±3.5% RH. Saturated sodium 
chloride solution was used in other storage chambers to create “high humidity” 
conditions at 78±3.5% relative humidity. The relative humidity was measured in the 
chambers throughout the study by a Traceable humidity and temperature pen (Control 
Company, Friendswood, TX). 
 
5.2.4 Scanning Electron Microscopy (SEM) 
To enhance the conductivity of the samples, all tablets were coated with a 15 nm 
thick platinum/palladium coating (80/20), applied by a Cressington Sputter Coater 208 
HR equipped with a thickness controller MTM 20 at 2.5 kV, 20 mA under Argon. Images 
were taken in field emission mode at 5 kV using a Zeiss Supra 40VP electron microscope 




5.2.5 Assay for Crystalline Surface Guaifenesin 
The use of x-ray diffraction and DSC to quantify surface crystallization was 
investigated, but these techniques were not well suited to determine the surface 
crystallization on tablets for this study. The limit of detection for crystalline-in-
amorphous samples by powder x-ray diffraction is 5 to 10% (31), and thus too high to 
capture early crystal growth. The sample preparation for DSC compromised the sample 
integrity, and sample size limits prevented analysis of the entire tablet surface area. 
Figure 5.2 shows the flow diagram of the assay used to quantify the amount of 
recrystallized guaifenesin from the entire tablet surface. The assay was based on the 
differential solubility of guaifenesin and the matrix polymer in an aqueous medium 
during a short immersion period. While the assay was not specific for crystalline drug, 
the test captured only drug located on the tablet surface, where SEM examination 
confirmed the presence of crystalline guaifenesin. Using tablets without surface crystals, 
baseline values were established for each formulation to account for amorphous 
guaifenesin located on the tablet surface accessible to the medium.  
 
Individual tablets were accurately weighed and a single tablet was placed into a 
large test tube (25x150 mm) filled with 3.0 mL of 0.1 N HCl. While the matrix polymer 
was insoluble in this medium, the acid dissolved the model drug guaifenesin. The test 
tube was subjected to vortex mixing (SP vortex mixer, Baxter Diagnostic, Deerfield, IL) 
at level 5 for 5 seconds, as timed by a stop watch. Immediately after vortex mixing, the 
medium was decanted and filtered through a 0.45 micron nylon filter. The filtered 
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medium containing the dissolved guaifenesin from the tablet surface was diluted in a 1-
to-1 ratio with fresh medium. 200 microliter of the diluted sample was analyzed at 275 
nm on a UV spectrometer (µQuant UV Spectrometer equipped with KC 4 software for 
data analysis, BioTek Instruments, Inc, Winooski, VT). Linearity was established for 
drug concentrations between 8 and 200 ng/mL (R2=0.9999). Concentrations of 2 ng/mL 
were below the limit of detection of the instrument. Residual liquid on the recovered 
tablets was blotted off and the tablets were dried under ambient conditions. The 
dimensions of dry tablets (height and diameter) were measured using calipers (Starrett, 
Athol, MA). Test conditions, including immersion time, vortex intensity, vessel size and 
dilution for the UV test, were chosen to ensure discrimination between samples.  
 
5.2.6 Moisture Uptake of Tablets 
Moisture uptake of stored tablets was measured by observing the mass loss on 
drying (LOD) of samples using a moisture-analyzing balance (AND MF-50 Moisture 
Analyzer, A&D Instruments, Abingdon, UK). Two gram samples were prepared by 
cutting the tablets with a utility knife into slices (thickness ca 0.2-0.5 mm), which were 
then arranged in a single layer in a pre-dried aluminum weighing pan. The percent loss on 
drying was recorded after heating the sample for 30 minutes at 110 °C. In addition to any 
moisture taken up during storage, formulations contained substances which partially 
volatilized under the test conditions, triethylcitrate and guaifenesin. To differentiate 
between the mass loss due to moisture and the mass loss due to other components, 
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excipient powders, extrusion blends and tablets, all stored at 17% RH as well as 78% 
relative humidity, were analyzed. The difference in the loss on drying results between 
tablets of the same formulation stored at either 78% or 17% RH was reported as the water 
uptake of the tablets.  
 
5.2.7 Mass Spectrometry (MS) 
Mass spectrometry was employed to identify the surface crystals. The surfaces of 
stored tablets, which had developed surface crystallization, were scraped with a clean 
razor blade in several locations. The removed material was transferred to a capillary tube 
(Kimax-51, Kimble, Vineland, NJ) which was melted shut  and analyzed on a Finnigan 
MAT TSQ 700 (ThermoFisher, Waltham, MA) using direct exposure probe desorption 
chemical ionization (DCI).   
 
5.3 RESULTS AND DISCUSSION 
The recrystallization of the model drug from the amorphous state was driven by the 
supersaturation of the drug in the polymeric matrix. However, other factors may 
influence the onset of crystal growth as well as the extent of crystallization. In addition, 
the crystal growth is localized and restricted to exposed surfaces of tablets (14), which 
has also been reported in glasses (32). This localization has been attributed to catalytic 
effects of solid impurities present on the interface, as well as to faster surface diffusion 
rates, while thermodynamic barriers for nucleation (the interfacial energy or the chemical 
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potential) were not altered (33). Another possible factor influencing surface crystal 
growth are stresses created by the growing crystals, which accounted for higher 
nucleation rates on surfaces of selenium films (34). 
 
5.3.1 The influence of talc on crystallization onset in melt extrudates with drug 
levels close to drug saturation solubility 
Nucleants are able to induce nucleation at lower supersaturation levels than 
necessary for homogeneous nucleation. To investigate if talc functioned as a nucleating 
agent for guaifenesin in melt extrudates, formulations with drug levels close to the 
saturation solubility were extruded, at lower drug levels than the other formulations in 
this study. Earlier film studies determined that Eudragit® L100-55 could solubilize about 
20% w/w guaifenesin (15), so the drug-to-polymer ratio of both formulations was chosen 
to be 19 parts guaifenesin in 81 parts Eudragit® L100-55 to be close to saturation 
solubility. Both formulations contained the same drug-to-polymer ratio and TEC, based 
on the polymer weight. One formulation contained 50% talc, based on total weight, while 
the control formulation was talc-free. To obtain tablets from extruded rods, the samples 
were broken rather than cut. This was done to avoid particulate contamination stemming 
from the knife blade, which could introduce additional particles to the newly created 




All samples were stored at 17% RH, and were observed under SEM after 1 and 4 
days. After 1 day, neither of the formulations showed crystal growth.  After 4 days, the 
control formulation without talc showed no recrystallization, while tablets containing talc 
had developed surface crystals. The drug-to-polymer ratio of 19:81 was close to the 
solubility limit of the drug in the polymer. Thus, the driving force for nucleation was low, 
and kinetic effects, such as the induction of nucleation by nucleating agents, became 
apparent by the reduction in the onset time of crystallization. The observations were 
consistent with talc acting as a nucleating agent for guaifenesin. Talc (20) and oxides, 
such as titanium dioxide (35), have been reported to influence crystallization behavior. In 
the absence of talc, the melt extrudates only contained components which softened or 
melted during the process, and hence no formulation component was present which could 
induce nucleation. Instead, air-borne particulates, impurities and other foreign particles 
could act as nucleating agents. Such contaminants could only be controlled by working in 
a clean room environment. Surfaces in talc-containing extrudates, on the other hand, were 
interspersed with talc particles, which presented readily available surfaces for 
heterogeneous nucleation and influenced how fast the onset of crystallization occurred.  
 
5.3.2 The influence of talc content and storage time on the quantity of surface 
crystals 
After determining that talc functioned as a nucleating agent for guaifenesin, it 
became necessary to quantify the effect of talc on surface crystal growth. A quantitative 
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assay was developed to determine the amount of recrystallized guaifenesin on the surface 
of tablets. The assay measured the amount of guaifenesin present on the entire tablet 
surface, both in the crystalline and the amorphous state. To account for amorphous 
guaifenesin, baseline values were determined for each formulation in freshly made 
tablets, in which surface crystallization was still absent. In Figure 5.3, Figure 5.6 and 
Figure 5.7, the baseline value is the “day 1” value on graphs. The baseline accounted for 
amorphous guaifenesin located in the matrix surface, where it was accessible to the 
medium during the test. When the measured guaifenesin amount in a sample exceeded 
the baseline value of this formulation, the additional amount of guaifenesin was 
considered to be crystalline guaifenesin which had developed up to this time point. This 
was a reasonable assumption, as electron microscopy confirmed the presence of 
crystalline material on tablet surfaces on storage.  
 
Tablets used for this study contained a drug-to polymer ratio of 37.5:62.5, and 
hence the matrix polymer was supersaturated with guaifenesin. Tablet samples were 
analyzed every 3 days for 15 days to follow the increase in surface crystal growth. The 
drug-to-polymer ratio and the TEC content for all tablets in this study were identical, and 
all tablets were stored at low relative humidity, 17% RH, and 24°C. Four formulations 
were investigated. The first formulation contained no talc. The second and third 
formulations contained 25 and 50% talc based on formulation weight, respectively, to test 
the concentration-dependence of the recrystallization on talc levels. The fourth 
formulation consisted of 15% guaifenesin in Acryl-EZE® as the matrix former, which 
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was included to investigate the effect of more than one non-melting component on 
guaifenesin recrystallization.  
 
Figure 5.3 follows the change in surface guaifenesin levels over 15 days. The 
amount of drug found with the assay was expressed as percentage of the total amount of 
guaifenesin in that tablet, which accounted for differences in weight between the samples. 
For tablets stored at 17% RH, the loss on drying values did not differ from those of the 
extrusion powder blend. This indicated that those tablets did not take up moisture during 
storage at low RH, and hence the results of the quantitative assay were not corrected for 
moisture uptake. Over 15 days, the amount of surface guaifenesin increased in all 
formulations, but the extent differed between formulations. Formulations containing no 
talc were found to have the lowest surface guaifenesin values after 15 days (0.15±0.03% 
of the total dose of guaifenesin), compared to 0.37±0.05% and 0.37±0.02% in tablets 
containing of 25% and 50% talc, respectively. These results show that the presence of 
talc increased surface crystallization of guaifenesin. However, doubling the talc 
concentration had no effect on guaifenesin recrystallization.  
 
These results indicate that the use of a common excipient in melt extrusion can 
induce changes in the physical state of the drug, which should to be considered when 
formulating solid dispersions. Talc was beneficial during melt processing as well as 
product handling and appearance. During hot-melt extrusion, it acted as a glidant, and 
thereby improved the flow of the powder blend in the hopper, increased melt flow at the 
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die, and decreased undesirable die-swell and tackiness in the extrudate. The resulting 
tablets had smoother surfaces and could be readily cut into tablets. To function in this 
manner however, the necessary talc levels were higher than the small percentages usually 
employed for nucleating agents. Kotek et al found that adding 0.03 wt% nucleant to the 
formulation maximized the crystallization of isotactic polypropylene, demonstrating the 
critical nucleant concentration (36). Other processes using high talc concentrations 
reported similar observations as in our study. For injection molding, the crystallization of 
the polymer was influenced by the nucleating effect of talc, but did not depend on talc 
concentrations, which ranged from 10 to 40% (20). Presumably, the high talc 
concentrations used in our study (25% and 50%) were well above the critical nucleant 
concentration, and thus no concentration-depended effect was found.  
 
After 15 days, the surface guaifenesin assay detected 0.27% of the total 
guaifenesin dose on Acryl-EZE®-containing matrix tablets. Since the initial assay on 
tablets without surface crystallization had detected 0.11% of the total guaifenesin dose, it 
was concluded that the additional 0.15% of the total guaifenesin dose had recrystallized 
on the tablet.  Surface crystallization for Acryl-EZE® matrix tablets was lower than 
expected based on its talc content. The efficacy of nucleating agents depends on both the 
system (35) as well as processing conditions (37). Paxton et al showed that good lattice 
matching of crystal and nucleant produced more crystals, and crystals attached to 
nucleant substrates had higher purity (38).  Presumably, the other components present in 
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Acryl-EZE® did not have good lattice matching with guaifenesin, and thus reduced 
nucleation and subsequent surface crystallization on the tablet surface. 
 
For all formulations, the amount of recrystallized guaifenesin was small compared 
to the total dose of the drug in the tablet. The relevance of these results will depend on 
whether the recrystallization can impact the performance of the tablets. In earlier studies, 
the recrystallization of guaifenesin had no effect on the drug release from the matrix 
tablet, since the high solubility of guaifenesin resulted in quick dissolution of the crystal 
layer on the tablet. However, a layer of hydrophobic drug crystals on a tablet surface 
could present a barrier to wetting the tablet, which could also slow the disintegration of 
the dosage form.  
      
5.3.3 Loss on drying (LOD) - water uptake of tablets stored at 78% RH   
Since the results of the surface guaifenesin assay were based on the mass of the 
tablet, the water uptake of tablets stored at 78% relative humidity was determined to 
correct for the weight of the moisture taken up during storage. The moisture content of 
tablets stored at 17% relative humidity did not differ from the moisture content of the 
melt extrusion powder blend; therefore no correction was made for the tablets stored at 
low RH. Formulations contained components which partially volatilized during the loss 
on drying test (triethyl citrate and guaifenesin). The LOD values of tablets stored at 17% 
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relative humidity were used to correct the LOD values obtained from tablets of the same 
formulation stored at 78% relative humidity 
 
Figure 5.4 shows the water uptake of melt-extruded tablets. At 78% relative 
humidity, extrudates containing 25% and 50% talc took up 2.74% and 1.98% moisture, 
respectively, while tablets without talc took up 4.36% moisture. Thus at high relative 
humidity after 15 days, tablets containing more polymer took up more moisture.  
The correlation between polymer content and moisture uptake was further investigated by 
storing powder samples of Eudragit® L100-55 as well as the talc used in this study at 
17% as well as 78% relative humidity. Figure 5.5 depicts the moisture uptake of excipient 
powders. After 9 days, the polymer powder absorbed 3.4% moisture, while the talc took 
up 0.13% water. Thus the moisture uptake of tablets was determined by the behavior of 
its components.  
 
5.3.4 Influence of relative humidity on guaifenesin recrystallization – continuous 
storage  
To investigate the influence of relative humidity during storage, tablets containing 
Eudragit® L100-55, 37.5% guaifenesin and no talc were stored in open containers for 15 
days. Figure 5.6 demonstrates the influence of elevated atmospheric moisture on the 
amount of guaifenesin surface crystallization under constant relative humidity conditions. 
After 15 days of storage, tablets stored at 17% relative humidity had an average of 
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0.15±0.0275% surface guaifenesin, compared with an average of 0.42±.01390% on 
tablets stored at 78% relative humidity. Relative humidity has been known to induce 
crystallization in many amorphous systems, including natural products such as sugars 
(29), whey powder (28) and milk powder (39), as well as drugs such as griseofulvin (40), 
indomethacin (41) and acadesine (42). Several mechanisms have been found to explain 
this phenomenon. Acadesine absorbs moisture to form an intermediary hydrate, which 
decomposes into the anhydrous form (42).  Crystallization can occur after absorbed water 
acts as a plasticizer and depresses the glass transition temperature of the matrix below the 
ambient temperature (29, 39). Relative humidity can also be a cause of heterogeneous 
nucleation as water droplets function as nucleating agents. Guaifenesin does not form 
hydrates, and the moisture uptake into the matrix was inversely correlated to surface 
crystallization. Therefore, the third possibility was considered to be the most likely 
explanation for the increased surface crystallization at high relative humidity. At high 
atmospheric humidity, more minute moisture droplets were present, which functioned as 
nucleating agents for guaifenesin on the tablet surface. It was the presence of droplets on 
the matrix surface, not the uptake of moisture into the matrix, which resulted in the 
nucleation-enhancing effect.  
 
Under constant relative humidity, the largest change in surface crystallization 
occurred over the first 3 days. After that time, the amount of surface crystallization 
increased more slowly. This is consistent with nucleation and initial growth taking place 
within the first 3 days, which quickly elevate the amount of recrystallized material on the 
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tablet surface. The continuing crystal growth adds new guaifenesin to the surface more 
slowly.  
 
5.3.5 Influence of relative humidity – RH cycling  
Relative humidity cycling is characterized by changing relative humidity 
conditions during storage. This is of practical importance, since intermediates or 
unpackaged products may be moved around facilities and could encounter uncontrolled 
humidity conditions. The impact of changing storage conditions on guaifenesin 
recrystallization is presented in Figure 5.7 and Figure 5.8. In study A, tablets stored under 
low relative humidity for 6 days were moved to a chamber with high RH for the next 6 
days, before being returned to the original low relative humidity conditions for the 
remaining 3 days. In the complementary protocol, study B, tablets stored at high RH for 
the initial 6 days were transferred to low RH conditions for 6 days before being returned 
to the high RH chamber for the last 3 days.  
 
Under all conditions studied, tablets containing talc were found to have higher 
levels of surface crystallization than the talc free tablets, for reasons presented in sections 
3.2 and 3.3. In study A, surface drug levels remained low and stable for 6 days, but rose 
about 4-fold when transferred to the high-humidity chamber. The surface drug levels 





In study B, the tablets containing talc had not yet reached the surface drug levels 
that were observed in the continuous storage experiment after 15 days when the tablets 
were switched to the low humidity environment. During the 6 days at low RH, no further 
increase in surface drug levels was observed, indicating that further drug recrystallization 
was either stopped or slowed. After returning to high RH storage, recrystallization levels 
quickly reached those of tablets stored continuously at high RH. Tablets containing no 
talc experienced the largest increases in surface crystallization within the first 6 days, and 
a change in storage RH did not affect surface drug levels.  
 
The surface drug levels in study A parallel the results of the continued storage at 
low RH for the first 6 days. The increasing surface drug levels can be attributed to 
additional surface crystallization induced by the storage humidity. The crystals, once 
present, were permanent, which is the reason that the surface drug levels remained high 
after the tablets were returned to the low RH chamber. So a transitory exposure to higher 
RH conditions can permanently alter the tablets by inducing surface crystal growth. The 
difference between surface drug levels at low and high RH can be a function of other 




5.3.6 Identity of surface crystals 
Mass spectrometry was employed to determine if the composition of the surface 
crystals was affected by the agents that stimulate crystal growth. All talc-containing 
formulations investigated in section 3.2 were evaluated. The mass spectra obtained from 
surface samples containing the drug crystals were compared to the mass spectrum of bulk 
guaifenesin. In all spectra, the base peak was detected at 199 m/z, which corresponded to 
the molecular mass of ionized guaifenesin. A peak detected at 397 m/z was due to dimer 
formation resulting from ion-ion interactions after ionization. The consistent presence of 
the guaifenesin base peak in all samples, and the existence of identical lower incidence 
peaks shared between all samples identified the samples as guaifenesin. No additional 
peaks were observed in any of the samples, indicating the absence of other components in 
the samples. The matrix polymer was not detected by MS since its molecular mass, about 
250,000 g/mol, was outside the scanned mass range. These results verified that the 
relative humidity during storage and talc in the formulation did not alter the chemical 
nature of the developing crystals. 
 
5.4 CONCLUSION 
This study investigated the influence of heterogeneous crystallization due to 
relative humidity in storage and talc as a formulation component on the amount of 
guaifenesin recrystallizing on the surface of melt-extruded matrix tablets. Tablets 
contained a constant guaifenesin-to-polymer ratio in a matrix of either Acryl-EZE® or 
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Eudragit® L100-55 and either no talc, 25% or 50% talc. Even at low supersaturation 
levels, talc-containing extrudates developed recrystallization earlier, as talc induced 
nucleation as nucleating agent. At higher drug levels (37.5:62.5 drug to polymer ratio), 
the presence of talc increased the quantity of drug crystals on tablet surfaces after for 15 
days (storage at 24°C and 17%RH). No concentration-depended effect of talc on the drug 
recrystallization was found, probably because both talc levels were above the critical 
nucleant concentration. Lower than expected crystal growth on Acryl-EZE®-containing 
matrix tablets demonstrated that the effects of several non-melting components were not 
additive. Relative humidity increased guaifenesin crystallization in tablets with and 
without talc, but recrystallization did not correlate with increased moisture uptake, 
indicating heterogeneous nucleation as a probable cause for this observation. Results 
from tablets stored transiently under high or low humidity conditions demonstrated the 
effect of relative humidity in storage on guaifenesin recrystallization was due to its effect 
on nucleation. The guaifenesin crystals, once they were induced, remained on tablet 
surfaces regardless of subsequent changes in storage relative humidity. This is an 
important consideration when working with intermediates and finished products 
containing amorphous components which might recrystallize. Formulation components 
and relative humidity conditions had no effect on the composition of surface guaifenesin 
crystals. Mass spectrometry indicated all crystalline samples recovered from stored 
tablets were identical to guaifenesin bulk material. In conclusion, both talc in the 
formulations and humidity during storage increased surface crystallization of guaifenesin 
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TEC (%) Talc (%) 
With talc - 9.3 39.8 1.9 49.0 
No talc - 18.3 77.9 3.8 - 
Acryl-EZE® 85.0 15.0 - - - 
0% talc - 36.4 60.7 2.9 - 
25% talc - 27.5 45.9 2.2 24.4 









Table 5.2 Component Functions 
 
Component Function 
Guaifenesin Model Drug 
Eudragit® L100-55 Polymeric matrix former 
Triethylcitrate (TEC) Plasticizer for Eudragit® L100-55 
Talc Glidant 
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Figure 5.3 The influence of talc content on the recrystallization of guaifenesin.  
 
All melt-extruded tablets contained the same guaifenesin-Eudragit® L100-55 ratio, 
and were stored at 24°C and 17% relative humidity, n=6. 
 
○ No talc 
∆ 25% talc 
□ 50% talc 
x Acryl-EZE® . 
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Figure 5.4. The influence of talc content on the water uptake of melt-extruded 
tablets.  
 
All melt-extruded tablets contained the same ratio of guaifenesin  to Eudragit® 
L100-55, storage at 24°C, n=3.  
 
○ No talc 
∆ 25% talc 
□ 50% talc 
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Figure 5.5. The influence of storage at 24°C and 78% relative humidity on the 
moisture content of excipient powders, n=3.   
 
















































Figure 5.6. The influence of relative humidity conditions during storage on the 
recrystallization of guaifenesin on the surfaces of tablets containing 36.4% 
guaifenesin, 2.9% TEC and 60.7% Eudragit® L100-55 
 
Storage temperature 24°C, n=6. 
 
○ Storage at 17% relative humidity 
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Figure 5.7 The effect of a temporary increase in relative humidity conditions on the 
surface crystallization of guaifenesin.  
 
The storage relative humidity was indicated by the dashed line, and the left y-axis. 
The individual symbols mark a guaifenesin amount, which can be read on the right 
y-axis. All melt-extruded tablets contained the same ratio of guaifenesin to 
Eudragit® L100-55, storage temperature 24°C, n=6. 
 
○ No talc 
∆ 25% talc 
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Figure 5.8. The effect of a temporary decrease in relative humidity conditions on the 
surface crystallization of guaifenesin. 
 
The storage relative humidity was indicated by the dashed line, and the left y-axis. 
The individual symbols mark a guaifenesin amount, which can be read on the right 
y-axis. All melt-extruded tablets contained the same ratio of guaifenesin to 
Eudragit® L100-55, storage temperature 24°C, n=6. 
 
○ No talc 
∆ 25% talc 




Chapter 6: The influence of aqueous film-coating on the 




This study investigated the effect of aqueous film-coating on the recrystallization of 
guaifenesin from acrylic, hot-melt extruded matrix tablets. After hot melt-extrusion, 
matrix tablets were film-coated with either hypromellose or ethylcellulose. The effects of 
polymer weight gain, curing conditions, storage temperature, and core guaifenesin 
concentration were investigated. The coating polymer was the most important factor 
determining the delay in the onset of crystallization, and crystal morphology was affected 
by the film coating. Ethylcellulose displayed a low solubility for guaifenesin, and at 
weight gains of either 7 or 15%, crystal growth occurred within 3 weeks (uncoated 
tablets: 30 minutes). Hypromellose was shown to have a high solubility for the drug, and 
at either 2 or 10% weight gain, films prolonged the onset of crystallization to 3-6 months. 
For a single polymer, greater film thickness resulted in a longer onset time of 
crystallization. Factors promoting drug and polymer diffusion, such as long curing times 
and elevated temperatures during both curing and storage, incomplete film coalescence 
and high core drug concentrations all contributed to an earlier onset of crystal growth. In 
conclusion, aqueous film coating of melt-extruded acrylic matrix tablets was 
demonstrated to retard the onset of recrystallization of amorphous guaifenesin, and the 





The physical stability of amorphous drugs in dosage forms remains a challenging 
area of research (1). Systems in which a drug is supersaturated are thermodynamically 
unstable, although the onset time of crystallization varies. Supersaturation results if the 
solubility of the drug in the matrix is exceeded and in hot-melt extrusion, the change in 
solubilities at the elevated processing temperatures, compared to storage temperatures, 
also contributes to supersaturation (2).  
 
The solubilization of drugs in polymeric matrices to form solid solutions has been 
investigated intensively. Earlier studies characterized the recrystallization of guaifenesin 
from the amorphous state on hot-melt extruded matrix tablets, and showed that extending 
the solubility of the drug in the matrix by adding hydrophilic polymers, in which the drug 
had a higher solubility, could reduce the amount of crystal growth (2). Subsequent studies 
demonstrated that formulation components, such as talc, and storage conditions, 
including humidity levels, can increase nucleation and crystal growth (3). In addition, the 
extrusion process used to manufacture the tablets (single-screw extrusion versus twin-
screw extrusion) affected the properties of melt-extruded tablets, including their physical 
stability, due to differences in drug dispersion achieved by the equipment (4). Since 
crystal growth occurred on tablet surfaces, we investigated how the modification of 
surfaces through the application of an aqueous polymeric film-coating affected the 




Polymeric materials have been used as barriers to diffusion in several applications, 
such as food products (5), packaging (6), membrane separations (7, 8) and sensors (9). 
Commercial film-coating systems have been developed to function as a moisture barrier 
(10). Relationships between water and gas permeabilities and membrane structure (11, 
12) have been described, and transport mechanisms and behavior of block copolymers 
have been reviewed by Jonquières et al (13). Polymer morphology impacts diffusion 
through the matrix: crystallinity have been reported to be a major factor in permeation 
(11, 12), and amorphous regions throughout the sample may differ in structure, resulting 
in heterogeneous molecular mobilities (14). Barrier properties can be enhanced by the 
addition of compounds to the  membrane that react with the molecules diffusing into the 
film (15).  
 
Two polymers were selected based on their presumed interaction with guaifenesin, 
as derived from their respective chemical structures. Ethylcellulose as a hydrophobic 
polymer was expected to provide a barrier to the diffusion of hydrophilic guaifenesin due 
to their structural differences. A hypromellose film was anticipated to slow guaifenesin 
diffusion through the film as it was able to interact with guaifenesin via hydrogen 
bonding. The objectives of this study were to investigate the effect of aqueous film-
coatings of hot-melt extruded matrix tablets on the physical stability of guaifenesin. The 
effects of polymer type, weight gain, curing time and temperature, storage conditions and 




6.2 MATERIALS AND METHODS 
6.2.1 Materials 
Guaifenesin was used as the model drug, and was purchased from Spectrum 
(Gardena, CA). Acryl-EZE®, which was donated by Colorcon (West Point, PA), and 
Eudragit® L100-55, which was a generous gift from Evonik-Degussa (Piscataway, NJ, 
particle size 95% below 250 micron) were employed as matrix formers. The melt-
extruded tablets were film-coated using Opadry® Clear YS-1-7006 (Polymer: 
hypromellose) and Surelease® (Polymer: ethylcellulose), which were donated by 
Colorcon (West Point, PA). FMC (Philadelphia, PA) provided Aquacoat® ECD 30 
(Polymer: ethylcellulose). Dibutylsebacate (DBS) was used to plasticize ethyl cellulose, 
and triethylcitrate (TEC) was used to plasticize Eudragit® L100-55, both were gifts from 
Vertellus (Greensboro, NC). Films to investigate the solubility in polymers were cast 
using Ethocel standard 7 Premium (NF grade) by Dow Chemical (Midland, MI). 200 
proof alcohol (USP grade) was purchased from AAPER Alcohol and Chemical Co 
(Shelbyville, KY). 
 
6.2.2 Tablet Preparation 
Tablets were prepared by hot-melt extrusion of the powder blends, followed by 
manual cutting of the extrudate strand. The formulations and the hot-melt extrusion 
parameters are presented in Table 6.1. Premixed powder blends were fed into a single-
screw Randcastle extruder (Randcastle Microtruder Model RCP-0750, Cedar Grove, 
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NY) equipped with a Nitralloy 135M screw (3:1 compression ratio with flight 
configuration containing feed, compression and mixing sections). The round die had a 
diameter of 6 mm. The processing temperatures chosen for extrudates containing either 
Eudragit® L100-55 or Acryl-EZE® and guaifenesin were 65°C, 75°C, 85°C (zones 1, 2, 
3, respectively) and 85°C (die). The extruder was equilibrated at the processing 
temperatures for a minimum of 40 minutes before extrusion. The extrudates were allowed 
to cool in a desiccator at room temperature for 1 day before manually cutting tablets. The 
tablets were packaged with one desiccant bag (one gram silica gel Minipax, Impak, Los 
Angeles, CA) into HDPE containers (MoldRite Plastics, Plattsburgh, NY), which were 
induction-sealed (Compak Jr, Enercon, Menomonee Falls, WI) and placed into 
appropriate storage chambers. The desiccant Drierite® (Hammond, Xenia, OH) was 
obtained from Fisher Scientific.   
 
6.2.3 Film-coating 
Hot-melt extruded tablets were mixed with compressed placebo tablets up to a 1:1 
weight ratio, and 300 gram batches (placebo plus melt-extruded tablets) were placed into 
a perforated pan-coater (HCT Mini HiCoater, Vector Corp, Cedar Rapids, IA), equipped 
with a peristaltic pump (505S Watson-Marlow, Wilmington, MA). The coating 
parameters are presented in Table 6.2. The coating dispersions were kept under constant 
low shear stir during preparation and the film-coating process. The tablets were coated to 
completion, and were dried for 10 minutes at the processing temperature in the rotating 
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pan. Some tablets were cured by placing them on open containers into ovens for the 
prescribed time. All tablets were stored in desiccators at 17% relative humidity until they 
were packaged.  
 
6.2.4 Film Preparation 
To investigate the solubility of guaifenesin in the coating polymers, drug-
containing films of hypromellose, ethylcellulose and Eudragit® L100-55 were cast, 
stored at 17% relative humidity, and observed for signs of crystallization. Films were 
prepared by dispersing 900 mg powder blend containing the polymer and different 
amounts of drug in 20-35 mL of 200 proof ethanol, DI water, or mixtures thereof. After 
stirring for at least 30 minutes under low shear until all components were dissolved or 
well dispersed, the solutions were cast into aluminum dishes (Fisher Scientific, Hampton, 
NH) and were dried for 24 hours or until dry under a fume hood (alcohol based films) or 
in a 55 °C oven (water based films).  
 
6.2.5 Powder X-Ray Diffraction  
Powder x-ray diffraction was used to study the morphology of guaifenesin and of 
the film-coating after SEM observations indicated crystal-like structures on the film. A 
coated tablet was arranged on a glass slide. The samples were scanned using a Philips 
Vertical Scanning Diffractometer, Type 42273 (Philips Electronic Instrument, Mount 
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Vernon, NY), employing CuKα radiation, operating at 40 kV and 30mA. The scan radius 
ranged from 10° to 60° degrees, and the step size was 0.05° every 4 seconds. 
 
6.2.6 Scanning Electron Microscopy 
Scanning electron microscopy (SEM) was used to study the surface morphology 
of the extrudates, and to investigate the recrystallization processes on the surface of the 
coated hot-melt extruded tablets. Samples were mounted on stubs with carbon tape 
(Shintron Tape, Shinto Paint Co, Ltd, Tokyo, Japan). To enhance the conductivity of the 
samples for SEM, all tablets were coated with a 15 nm thick platinum/palladium coating 
(80/20), applied by a Cressington Sputter Coater 208 HR (Watford, UK) equipped with a 
thickness controller MTM 20 at 2.5 kV, 20 mA under Argon. SEM images were taken in 
field emission mode at 5 kV using a Zeiss Supra 40VP electron microscope 
(Minneapolis, MN) equipped with a Gemini Column and SmartSEM software. The 
surface of the tablets was surveyed, and a representative area was chosen for the 
micrograph. 
 
6.2.7 Assay for Surface Guaifenesin 
An assay was developed to quantify the amount of guaifenesin on the tablet 
surface. Briefly, individual tablets were accurately weighed and a single tablet was placed 
into a large test tube (25x150 mm) containing 5.0 mL of 0.1 N HCl. The test tube was 
subjected to vortex mixing (SP vortex mixer, Baxter Diagnostic, Deerfield, IL) at a fixed 
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agitation force for 5 seconds. Immediately after vortex mixing, the medium was decanted 
and filtered through a 0.22 micron nylon filter (Puradics 25NYL syringe filter, Whatman, 
Maidstone, UK). The filtered medium containing the dissolved guaifenesin from the 
tablet surface was analyzed by UV analysis. Residual liquid on the recovered tablets was 
blotted off and the tablets were dried at ambient conditions. The dimensions of dried 
tablets (height and diameter) were measured using calipers (Starrett, Athol, MA).  
 
6.2.8 UV Analysis of Guaifenesin  
The guaifenesin content of samples from the surface guaifenesin assay was 
quantified at 273 nm in 400 microliter samples by UV spectroscopy (µQuant UV 
Spectrometer equipped with KC 4 software for data analysis, BioTek Instruments, Inc, 
Winooski, VT). Linearity was established for drug concentrations between 8 and 200 
ng/mL (R2=0.9968). Concentrations of 2 ng/mL were below the limit of detection of the 
instrument. 
 
6.3 RESULTS AND DISCUSSION 
6.3.1 Choosing the coating polymers 
At a drug concentration above the solubility limit, guaifenesin recrystallized from 
the amorphous state. Earlier studies characterizing hot-melt extruded matrix tablets which 
contained Eudragit® L100-55 and guaifenesin found that the drug concentration in the 
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matrix, the presence of nucleating agents and the processing conditions influenced the 
physical stability of guaifenesin (2-4). 
 
The solubility of guaifenesin in both polymers and in Eudragit® L100-55 was 
measured by casting films containing one of the polymers and dissolved drug in 
increasing concentrations, and observing the physical stability during storage for 5 
months at 17% relative humidity (Table 6.3). Recrystallization occurred in ethylcellulose 
films with 1% guaifenesin content, while hypromellose films solubilized 40% drug under 
the same conditions. Earlier studies found that the matrix-forming acrylic polymer, 
Eudragit® L100-55, could dissolve 20% guaifenesin (16).  
 
Guaifenesin (Figure 6.1 a) is a hydrophilic molecule, with alcoholic and ether 
functional groups which enable it to hydrogen-bond to corresponding groups in the 
hydrophilic polymer hypromellose (Figure 6.1 b), while ethyl cellulose (Figure 6.1 c) is a 
hydrophobic material, whose lack of hydrophilic groups offers little hydrogen bonding 
interaction potential. Studies on barrier membranes indicated transfer by diffusion of 
small molecules depended on the intensity of interactions between the diffusing species 
and the polymer (14) Earlier studies from our group demonstrated that polymers with a 
higher solubility for guaifenesin than Eudragit® L100-55, such as hypromellose, were 
able to enhance the drug’s solubility in a hot-melt extruded matrix when they were co-
extruded with the acrylic polymer (2). By solubilizing guaifenesin, coating polymers 
function as a reservoir for the drug, and reduce guaifenesin supersaturation levels. In 
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addition, a polymeric film around a tablet minimizes the exposure of the amorphous drug 
to the environment containing impurities and moisture droplets, which can function as 
nucleating agents. 
 
6.3.2 Film-coating of hot-melt extruded tablets  
All coating operations were conducted in a perforated pan-coater (HCT HiCoater 
Mini). Coating parameters (Table 6.2) were chosen to promote complete film-formation 
and to minimize sticking and twin-formation. The tablets derived form hot-melt 
extrudates were initially flat-faced and cylindrical, a shape that can pose sticking 
problems during film-coating, regardless of the method used to prepare tablets (17). The 
elevated coating temperatures (35-45°C) softened the matrix, and Eudragit® L100-55 
matrix tablets experienced sticking and twin-formation to a higher degree than Acryl-
EZE® matrix tablets, since the talc in Acryl-EZE® functioned as a glidant and reduced 
stickiness of tablets. To counteract the sticking and twinning, the coating batch was made 
up of hot-melt extruded matrix tablets mixed with smaller, deep concave placebo tablets. 
These compressed tablets did not soften, and acted as spacers and buffers to reduce 
impacts between two hot-melt extruded tablets, reducing the number of twins. 
 
A second phenomenon observed in the coating of hot-melt extruded tablets was 
the spheronization of the initially flat-faced tablets during film-coating. Tumbling the 
tablets in the coater at the processing temperature and RPM without spraying the coating 
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dispersion, or spraying deionized water at the same rate as the coating dispersion did not 
reproduce this effect. Spheronization was attributed to the presence of plasticizers in the 
coating dispersions, which diffused into the tablets and plasticized the matrix and, 
combined with the tumbling action of the pan, resulted in the change of tablet shape. In 
addition to the coating conditions, the age of the tablets (time after melt-extrusion) was of 
importance. Spheronization only occurred if the film-coating occurred within a few days 
of hot-melt-extrusion due to the development of surface crystallization on the tablets. 
Initially, small amounts of crystals are dispersed over the surface area of the tablet. As 
the recrystallization increased, a harder “crust” of crystals enveloped the tablet, which 
subsequently resisted deformation. 
 
6.3.3 The influence of the film-coating layer on guaifenesin recrystallization 
 
The recrystallization of guaifenesin from the amorphous state, which occurred 
within 30 minutes in uncoated tablets containing the same drug concentration as the 
coated tablets, was delayed when tablets were coated with either polymer. The polymeric 
film around the tablets separated the supersaturated matrix from exposure to the 
atmosphere containing impurities and moisture droplets. Bruce et al demonstrated that 
moisture can exert a nucleating effect on guaifenesin, which increased guaifenesin crystal 




When crystal growth appeared on film-coated tablets, the crystal morphology was 
altered compared to the crystals on uncoated tablets (Figure 6.2). While needle-shaped 
crystals grew outward in uncoated tablets, they developed within the film-coatings, and in 
hypromellose films, their habit changed. The identification by powder x-ray diffraction 
failed, as the amount of crystalline guaifenesin in the samples was below the detection 
limit of the matrix (about 5% (18) to 10% (19), Figure 6.3). The change in crystal habit in 
the presence of polymers (20) as well as polymer and surfactant combinations (21) has 
been reported, and was explained by viscosity effects and the preferential adsorption of 
polymers to some crystal faces due to hydrogen bonding, which retards the growth of 
those sites. The faster relative development of other crystal faces then changes the 
appearance of the crystal. Katzhendler et al describe a detailed mechanism for the 
hydrogen bonding interaction of carbamazepine and hypromellose to explain the 
polymer’s effect on the drug (22). The change in the crystal habit of miconazole 
increased drug release from mucoadhesive patches (23), although no effect of 
recrystallization on drug release was found with the present system (2).  
 
6.3.4 The influence of polymer type on guaifenesin recrystallization 
 
Hypromellose prolonged the onset of drug release for 3-6 months (Table 6.5), 
while recrystallization in ethyl cellulose-coated tablets occurred within 3 weeks (Table 
6.6). An assay detecting the guaifenesin present on the tablet surface was employed to 
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follow the increase in surface guaifenesin during storage (Figure 6.4). Determining the 
coating thickness before and after the test (Figure 6.5) showed that only the upper coating 
layer was dissolved in the assay due to the short immersion time, thus the assay captured 
guaifenesin present in the coating layer, and not from the matrix tablet. Hypromellose, 
was more efficient in delaying recrystallization. Polar interactions of drug and polymer 
facilitated guaifenesin solubilization, and delayed the onset of crystallization. Peppas et al 
found that drug-polymer binding impeded drug diffusion in hydrogels (24). Interactions 
between diffusants and polymers contribute to mass transport phenomena, and the 
diffusion through solid polymeric networks is complex (5). 
 
Ethylcellulose was less effective than hypromellose in delaying the onset of 
guaifenesin, which was probably due to the amphiphilic nature of guaifenesin (it 
possesses a benzene ring, and short aliphatic chains), which enabled the transport through 
the hydrophobic ethylcellulose membrane. The low solubility of ethylcellulose for 
guaifenesin would quickly result in supersaturation of the film, followed by crystal 
growth on the surface.  
 
6.3.5 The effect of weight gain and polymer film thickness 
In both polymers, a higher polymeric weight gain prolonged the onset of 
crystallization (Table 6.5, Table 6.6). Increasing the hypromellose weight gain from 2% 
to 10% resulted in an increase in film thickness from 191 micron to 358 micron and a 
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delay in the onset of crystal growth form 3 to 5 months under identical storage 
conditions. A thicker film involves longer diffusion paths, and has a higher polymeric 
volume, which can solubilize higher amounts of drug. Such a film takes longer to reach 
supersaturation levels that trigger nucleation and crystal growth. However, polymer 
weight gain was not a predictor of the onset time of crystallization when comparing two 
different coating polymers. The data in Table 6.4 show that the higher film thickness of 
ethylcellulose coatings did not delay crystallization compared to hypromellose films 
(Table 6.5). The polymer type had a much larger influence on crystal growth than the 
film dimensions. 
 
6.3.6 The effect of temperature during curing and in storage  
 
Tablets stored at higher temperatures developed recrystallization earlier (Table 
6.5). Drug diffusion in polymers has been investigated by Zhao et al by molecular 
modeling of aspirin in polymer blends (25). The “wiggling” of polymer chains was found 
to be more important for the drug diffusion than its free volume. Free volume and 
average cavity size have been identified as a major factor in the diffusion of smaller gas 
molecules (carbon dioxide, oxygen) as part of the “hopping diffusion mechanism” (26-
28). Zhao et al proposed that due to the bigger size of drug molecules compared to the 
gases, aspirin could not skip-jump between different cavities of free volume in the 
polymer, but rather moved forward with the wiggling of the polymer chains. This concept 
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is useful in explaining the observations made in this study. The change in crystallization 
rates with temperature in amorphous drugs were studied by Aso et al (29), who ascribed 
faster crystallization in part to higher molecular mobility. In general, the kinetic energy of 
molecules increases with temperature, resulting in higher molecular mobility and a faster 
diffusion of drug molecules through the polymer strands.  
 
Curing is performed to complete film coalescence after film-coating. 
Hypromellose-coated tablets were cured for 24 hours at 40°C, and complete coalescence 
was observed in all cases, which was another factor influencing their effectiveness to 
prevent recrystallization. 
 
In ethylcellulose-coated tablets, film coalescence and the prevention of 
recrystallization posed conflicting goals. Since film coalescence in uncured tablets was 
incomplete after coating (cracks in the film were visible under SEM directly after the 
process), a curing step was necessary to conclude film formation. Curing for 24 hours at 
60°C was effective in attaining film coalescence, as observed under the SEM. However, 
in tablets cured at 60˚C for 24 hours, crystal formation was observed after one week 
regardless of matrix composition. Crystallization in uncured tablets differed despite equal 
storage conditions. Some tablets showed crystal growth, while others were crystal free. 
This was ascribed to different degrees of film formation in these tablets. Cracks in the 
film due to incomplete film formation resulted in easier access to the surface, while 
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curing at elevated temperatures promoted drug migration into the film. Both mechanisms 
hastened drug recrystallization.  
 
6.3.7 The effect of drug-to-polymer ratio in the core tablet composition 
Table 6.6 shows the impact of drug concentration in the core on the onset of 
guaifenesin crystal growth. For both matrix formers, a higher guaifenesin levels in the 
core tablets resulted in a higher drug-to-polymer ratio and an earlier onset of crystal 
growth, since the supersaturation of guaifenesin in the matrix was the driver for the 
recrystallization from the amorphous state.  
 
6.4 CONCLUSION 
The film-coating of hot-melt extruded acrylic matrix tablets containing guaifenesin 
was investigated. Film-coating delayed the onset of crystallization over uncured tablets 
regardless of the polymer used for the coating, which was ascribed to the protection of 
the amorphous drug from ubiquitous nucleating agents by covering the tablet surface. 
The drug morphology of guaifenesin crystals was altered due to the presence of 
polymers. Most formulation and processing factors investigated (polymer type; weight 
gain; curing time and temperature; storage conditions; and core drug-to polymer ratio) all 
affect diffusion, and promoting diffusion of either guaifenesin or the polymer resulted in 
an earlier onset of recrystallization. The choice of coating polymer was the largest single 
factor affecting the onset time of crystallization. In conclusion, the film-coating of hot-
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melt extruded, acrylic matrix tablets successfully delayed the onset of guaifenesin 
recrystallization for up to 6 months. 
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6.7 TABLES  
 
 
Table 6.1 Formulation and extrusion parameters of hot-melt extruded tablets  
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Table 6.2 Coating parameter  
 
Coating Polymer Aquacoat®ECD Opadry® 
Apparatus HiCoater HCT Mini HiCoater HCT Mini 
Batch Size 300 g 300 g 
Spray Air 0.25 kg/cm2 0.25 kg/cm2 
Spray Rate 1.5 g/min 2.0 g/min 
Inlet Air 55-60 °C 75 °C 
Outlet Air 41°C 42°C 
Pan Speed 40 RPM 20 RPM 
Drying 10 min 10 min 
Curing 60°C/2 hrs or none 40°C/2 hrs 
Solids Content 20 10 









Table 6.3 The solubility of guaifenesin in the coating polymers  
 




Drug concentration at which 
crystallization was first visible % w/w 
Ethylcellulose 1% 








Table 6.4 Film thickness of coated tablets.  
 





Film Thickness  (lower 
tablet weight gain) 
(µm) 
Film Thickness (higher 
tablet weight gain) 
(µm) 
Opadry® 191.4 358.2 







Table 6.5 The effect of hypromellose weight gain and storage conditions on the onset 
time of crystallization for melt-extruded matrix tablets coated with hypromellose.  
 












2% 10% 2% 10% 
Onset at 
25˚C/60%RH 
4 Months 6 Months - 6 Months 
Onset at 
40˚C/75%RH 





Table 6.6 The effects of guaifenesin concentration in matrix tablets containing either 
Eudragit® L100-55 or Acryl-EZE® on the recrystallization of guaifenesin from the 
amorphous state.  
 
Tablets were cured for 2 hours at 60˚C and were stored in induction-sealed 
containers at 40˚C/75% relative humidity. 
 
Matrix former Eudragit® L100-55 Acryl-EZE® 
Guaifenesin 
Concentration 
20% 25% 20% 37.5% 
24 Hours after 
Coating 
no no no no 
2 Weeks no yes no yes 
3 Weeks yes yes yes yes 
No – tablet surface was free of crystal growth 












Figure 5.1 (b). Hypromellose (taken from Ref (31)) 
 
 













Figure 6.2 The influence of coating polymers on the growth of guaifenesin crystals. 
 













Figure 6.3 The influence of 4 months of storage at 25˚C/60% relative humidity on 
the surface morphology of film-coated matrix tablets. 
 
PXRD scan at 40 kV and 30mA. The scan radius ranged from 10° to 60° degrees, 
and the step size was 0.05° every 4 seconds. 
 
A-Acryl-EZE® tablets coated with Opadry 4 months 
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Figure 6.4 The influence of storage time on the recrystallization of guaifenesin hot-
melt extruded matrix tablets film-coated with Opadry  
 
10% polymer weight gain, n=6.  
 
◊ - 25 C/60%RH Eudragit® L100-55                       □ - 25 C/60%RH Acryl-EZE® 

























































Figure 6.5 Influence of the quantitative analysis process on the film thickness of 
Opadry-coated tablets  
 
n= minimum of 6 individual measurements. 
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Chapter 7: Properties of extruded tablets produced by either single-




This study investigated the effect of single-screw extrusion (SSE) and twin-screw 
extrusion (TSE) on the properties of melt-extruded tablets containing guaifenesin and 
diltiazem hydrochloride (DIL) in an acrylic matrix. Tablets containing both drugs in a 
matrix of Eudragit® L100-55 were produced by extruding powder blends on either a 
single-screw (Randcastle Microtruder) or on a twin-screw extruder (Haake MinilabII 
Microcompounder) at three different temperatures, 75, 95 and 125°C. Tablets containing 
guaifenesin and the same acrylic polymer were extruded at five separate temperatures 
between 65 and 125 °C. Thermal analysis demonstrated that guaifenesin solubilized DIL, 
and plasticized Eudragit® L100-55, while DIL did not affect properties of guaifenesin or 
the polymer. Powder x-ray diffraction (PXRD) of guaifenesin-containing tablets extruded 
on the single-screw extruder at lower processing temperatures (65°C) demonstrated 
partial crystallinity of the drug, which was absent in tablets produced by twin-screw 
extrusion at the same temperature. Extrusion at 125°C resulted in amorphous extrudates 
in both units. Energy dispersive spectroscopy (EDS) of DIL-containing tablets revealed 
drug clusters in tablets produced at low temperatures on both extruders, while the drug 
distribution improved with processing temperature. Regardless of extrusion temperature, 
the twin-screw extruder yielded extrudates in which the DIL was more homogeneously 
dispersed. To study the effect of drug dispersion on tablet properties, drug content in 
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tablets, drug release profiles and physical stability of guaifenesin were investigated. 
Heterogeneous drug dispersion at the microscopic level did not translate into differences 
in drug content for an entire tablet. Drug release in phosphate buffer pH 6.8 was 
dominated by matrix erosion, and was not influenced by processing temperature and 
extruder type. In simulated gastric fluid without pepsin, tablets extruded at 125°C on the 
twin-screw extruder showed a significantly lower drug release rate than other 
formulations. This can be attributed to higher matrix integrity after surface drug 
dissolution due to a high degree of drug dispersion. Guaifenesin was physically unstable, 
as it was rendered amorphous by the extrusion process, and recrystallized on storage due 
to supersaturation in the matrix. An assay for quantifying guaifenesin surface 
crystallization demonstrated that formulations extruded on the twin-screw extruder 
developed less surface crystal growth than single-screw extrudates over 16 days. The 
more homogenous drug distribution achieved by twin-screw extrusion resulted in lower 
local guaifenesin supersaturation levels, which reduced the driving force of 
crystallization. This study demonstrated that properties of melt-extruded tablets depended 





Hot-melt extrusion is a versatile processing technique (Crowley et al., 2007, Repka 
et al., 2007, Repka et al., 2002) which enables the production of solid solutions of poorly 
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water soluble drugs (Breitenbach, 2002, Forster et al., 2001, Leuner and Dressman, 
2000). Blends are fed into the heated barrel, and the mass is conveyed towards the die by 
one (single-screw extruder) or two (twin-screw extruder) rotating screw(s). While the 
residence time in the extruder barrel at elevated temperatures is in the order of minutes, a 
number of unit operations can be performed in an extruder (Riaz, 2000), including 
pumping and conveying, mixing and compounding as well as venting of gases.  
 
Typical pharmaceutical compositions contain an active ingredient blended with a 
matrix former, glidant, release modifier and other excipients. Extrusion can occur above 
or below the melting point of the active ingredient. Solid solutions (Leuner and 
Dressman, 2000) form when the drug melts under the processing conditions, and is 
molecularly dispersed in the polymer (or the polymer blend). When the melting point of 
the drug lies above the extrusion temperature, the drug can dissolve in the molten 
polymer, or another matrix component such as citric acid (Schilling et al.), resulting in a 
solid solution. In a solid dispersion, the drug particles are finely dispersed throughout the 
matrix, but do not dissolve in the matrix. The physical state and degree of mixing in the 
melt are “frozen” in place as the extrudate cools after exiting the die. 
 
The physical stability of such solid solutions depends on the concentration of the 
active and its solubility in the matrix. Earlier studies demonstrated a 20% w/w solubility 
of guaifenesin in Eudragit® L100-55 (Dietzsch et al., 2005), and extrudates with a drug 
concentration below the solubility limit were physically stable over the 6 month study. 
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When the solubility limit was exceeded, the amorphous compound recrystallized within 
30 minutes at a guaifenesin concentration of 37.5%. (Bruce et al., 2007a).   
 
Mixing increases the tendency towards uniformity in a formulation. The mixing of 
polymers in melt extrusions has been discussed by Rauwendaal (Rauwendaal, 1991) and 
White (White et al., 2001). If the active does not melt during the process, the particles can 
be reduced in size or deagglomerated (dispersive mixing) or are just homogeneously 
blended with the melt (distributive mixing), depending on the processing conditions and 
extruder specifications. Thermal homogenization refers to distributive mixing in liquids. 
In melt extrusion, the screw design determines whether distributive or dispersive mixing 
will dominate the mixing action of a particular screw or screw element. This is 
determined by the shape of the screw, and how it interacts with the melt. Distributive 
mixing occurs as the melt flow is divided and recombined, while stretching and folding 
promote dispersive processes. In twin-screw extruders, the mixing effect of the screw can 
be customized by assembling the screw using several smaller units which can have 
different designs and thus differ in their mixing action.  
 
Mixing in single-screw extruders is influenced by a number of factors, and different 
screw designs exist to enhance mixing. The channel depth in flighted screws decreases 
along the length of the screw,  compressing the material as it moves toward the die, 
which does not promote homogeneous distribution (Luker, 2003). Material properties 
influence the transport in the barrel, since it depends on frictional interactions between 
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the material, the screw and the barrel (Wildi and Maier, 1998). The feeding rate 
influences the mean transit time and filling of the barrel, which affects the mixing 
efficiency and extrudate properties in products extruded on a single-screw extruder (Ding 
et al., 2005, Luker, 2003, Yeh et al., 1992). Extruder screws are divided into sections to 
perform different unit operations; a typical set-up successively includes a feeding, 
melting and a metering section, and then the die. Mixing often occurs close to the die, 
when the material in the barrel is fully melted, and viscosity is near its minimum to take 
advantage of the pressure generated upstream (Luker, 2003). This arrangement is well 
suited for melt homogenization (distributive mixing), but reduces the ability of the 
extruder to perform dispersive mixing, which requires a higher stress rate to overcome 
the yield points of the morphological units that are to be reduced in size. In recent years, 
improved single-screw extruder screw designs (Markarian, 2004) have been developed 
which increase distributive and dispersive mixing and enable venting.  
 
Material transport in co-rotating twin-screw extruders works by the same 
fundamental mechanism, but the presence of the second screw decreases the dependence 
on material properties (Dreiblatt, 2003). In twin-screw extrusion, the two screws can be 
configured with elements that perform different processes, including forwarding, 
distributive or dispersive mixing, and zoning (White et al., 2001). Such a set up can be 
customized for a specific application by combining screw elements of different designs. 
These extruders can also accommodate additional feeds further down the barrel, enabling 
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the introduction of temperature-sensitive substances into the molten, compounded matrix 
to minimize the exposure to higher temperatures necessary to prepare the matrix.  
 
The effect of extruder type on product properties has been investigated for the 
dispersion of fillers in polymers (Cho and Paul, 2001, Dennis et al., 2001). In these 
studies, twin-screw extrusion yielded more uniform products, and was able to exfoliate 
the filler clays due to better dispersive mixing in these extruders. Lower levels of filler 
were necessary to achieve similar improvements in mechanical properties in composites 
produced by twin-screw extrusion (Wu et al., 2002). However, complete homogeneity is 
not always necessary to improve the properties of extruded products. Six et al 
demonstrated that the melt-extruded dispersions of itraconazole with hypromellose had a 
heterogeneous composition (Six et al., 2003), yet the dissolution rate of an extruded 
itraconazole matrix was comparable to the commercial Sporonox® formulation (Six et 
al., 2005). 
 
The current study was undertaken to investigate the behavior of blends containing 
guaifenesin and diltiazem hydrochloride (DIL), drugs with a low and a high melting 
point, respectively, in melt extrudates and to compare the mixing efficiencies of a single-
screw extruder and a twin-screw extruders on a molecular level, followed by as 
assessment of how the degree of mixing translated into differences in tablets properties 
produced by these two techniques. The objectives of this study were, first, to characterize 
the thermal properties of guaifenesin-DIL blends, and to measure their effect on the 
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matrix former, Eudragit® L100-55. Secondly, the goals of this study were to examine 
drug morphology (in guaifenesin-containing tablets) and the drug distribution (in DIL-
containing extrudates) of melt-extruded tablets produced by either single-screw or a twin-
screw extrusion and to investigate the effect of extruder type on the drug content of the 
extrudates, their dissolution rate, and the recrystallization of guaifenesin from the 
amorphous state on storage.  
 
7.2 MATERIALS AND METHODS 
7.2.1 Materials 
 
Guaifenesin and diltiazem hydrochloride (DIL) were purchased from Spectrum 
(Gardena, CA). DIL was sieved, and only the particle fraction smaller than 75 micron 
(200 mesh) was used for this study. Eudragit® L100-55 was provided by Evonik Degussa 
(Piscataway, NJ, particle size 95% below 250 micron). Colloidal silicon dioxide (Cab-O-
Sil M-5P, Cabot Corporation, Alpharetta, GA, average particle size 0.2-0.3 micron) was 
kindly donated by Cabot. The desiccant Drierite® (Hammond, Xenia, OH) was obtained 
from Fisher Scientific.   
7.2.2 Tablet Preparation 
 
Tablets were prepared by hot-melt extrusion of powder blends on either a single-
screw (SSE) or a twin-screw extruder (TSE), followed by manual cutting of the extrudate 
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strand. The formulations are presented in Table 7.1. To prepare tablets by single-screw 
extrusion, premixed powder blends were fed into a Randcastle extruder (Randcastle 
Microtruder Model RCP-0750, Cedar Grove, NY) equipped with a Nitralloy 135M 
flighted screw (L/D ratio 42, 3:1 compression ratio with flight configuration containing 
feed, compression and mixing sections). The round die had a diameter of 6 mm. The 
three heating zones and the die were equilibrated at the processing temperatures for a 
minimum of 40 minutes before extrusion. Extrusions were carried out at constant 
temperatures, only the feeding zone (in the single-screw extruder) and the force feeder (in 
the twin-screw extrusion) were set to lower temperatures to facilitate material flow into 
the extruder. In the single-screw extruder, the first temperature zone (feeding section) 
was set to 65°C for all extrusions, and the remaining two temperature zones (melting and 
metering sections) and the die were set to the same temperature for any given extrusion. 
To extrude guaifenesin-containing tablets (formulation I), separate extrusions were 
carried out at 65, 75, 85, 95 and 125°C. Tablets containing guaifenesin and DIL 
(formulation II) were extruded at 75, 95 and 125°C. Identical powder blends were 
processed at the same temperatures on a twin-screw extruder, (Haake Minilab II 
Microcompounder, ThermoScientific, Waltham, MA) equipped with a single heating 
zone, a conical flighted screw (L/D ration 7.82-21.9), a water-cooled force-feeder and a 
round die (diameter 2 mm). The melt was not circulated through the back-flow channel. 
Processing parameters are listed in Table 7.2. All extrudates were allowed to cool at room 




7.2.3 Thermal analysis 
Differential scanning calorimetry (DSC) was used to determine the melting points 
of guaifenesin and diltiazem hydrochloride in binary powder blends and in the extrusion 
blend. Modulated DCS (MDSC) was used to determine the glass transition temperature 
of Eudragit® L100-55 in mixtures with the drugs and the extrusion blend. All powder 
blends were prepared in a ceramic mortar and pestle. Three to seven milligram samples 
were analyzed in crimped aluminum pans (Kit 0219-0041 Perkin-Elmer Instruments, 
Norwalk, CT) on a calorimeter (Thermal Advantage Model 2920, TA Instruments, 
Newcastle, DE) equipped with Thermal Advantage Instrument Control Software and 
Universal Analysis 2000. Ultra pure nitrogen was used as a purge gas at a flow rate of 
150 mL/min. per minute. The DSC analysis was conducted from 50 to 230°C at a heating 
rate of 10°/minute. MDSC determinations proceeded from 50 to 170°C at a heating rate 
of 15°C/minute with a temperature amplitude of 0.5° every 40 seconds. 
 
7.2.4 Powder X-Ray Diffraction  
Powder x-ray diffraction was used to study the crystalline or amorphous state of 
drug and polymer in extrudates and the physical mixture containing guaifenesin. The 
powder samples were screened prior to analysis, and a thin powder layer was prepared. 
Cross-sections of extrudate rods were placed on sample holders. The samples were 
scanned using a Philips Vertical Scanning Diffractometer, Type 42273 (Philips 
Electronic Instrument, Mount Vernon, NY), employing CuKα radiation, operating at 
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40kV and 30mA. The scan radius ran from 10° to 40° degrees, and the step size was 
0.02° every 2 seconds. 
 
7.2.5 Scanning Electron Microscopy (SEM) and Energy-Dispersive Spectroscopy 
(EDS) 
To study the effect of processing temperature as well as extruder type on the 
tablet morphology and the molecular dispersion of the drug within the extruded matrix, 
tablets containing DIL were prepared by either single-screw or twin-screw extrusion, and 
analyzed by SEM-EDS. To enhance the conductivity of the samples for SEM, all tablets 
were coated with a 15 nm thick platinum/palladium coating (80/20), applied by a 
Cressington Sputter Coater 208 HR (Watford, UK) equipped with a thickness controller 
MTM 20 at 2.5 kV, 20 mA under Argon. SEM imaging and EDS mapping were carried 
out using a LEO 1530 electron microscope (LEO Electron Microscopy, Thornwood, NY) 
equipped with a Gemini field emission column and a Gresham Sirius 10 detector (e2v 
scientific instruments, Woburn, UK) for EDS. SEM micrographs were captured at 10 kV 
using LEO-32 software.  EDS mapping of carbon, oxygen and chlorine present in the 
sample was carried out using EDS2006 software (IXRF systems, Houston, TX).  Each 
sample was investigated in both cross-sections as well as longitudinal sections through 





7.2.6 Drug Content Determination 
The drug content was determined to study the drug distribution in the extrudates. 
Thin sections of the extruded rods were accurately weighed and placed in volumetric 
flasks containing 100.0 mL of phosphate buffer pH 6.8 (n=3). After the sections had 
dissolved, the medium was filtered through a 0.22 micron nylon filter (Puradics 25NYL 
syringe filter, Whatman, Maidstone, UK). The drug content of each sample was analyzed 
by UV testing as described in section 2.8. 
 
7.2.7 In-Vitro Drug Release Testing 
Dissolution testing was performed to study the drug release properties of tablets in 
a USP 30 Apparatus 1, basket method (Varian Industries, Inc. VK 7000, Palo Alto, CA) 
equipped with an auto sampler (Varian VK 8000, Palo Alto, CA). Dissolution studies of 
guaifenesin tablets were conducted in 900 mL 0.05 M phosphate buffer pH 6.8 (n=3) at 
37°C and 50 rpm for 8 hours. Dissolution studies on melt-extruded tablets containing 
DIL and guaifenesin were conducted in 900 mL simulated gastric fluid without pepsin 
(n=3) at 37°C and 50 rpm for 8 hours. At the end of each dissolution test, complete drug 
release was obtained by mixing the vessel contents with a homogenizer for one minute to 
ensure total disintegration of the tablets. The dissolution samples were filtered through a 
0.22 micron nylon filter (Puradics 25NYL syringe filter, Whatman, Maidstone, UK) to 




7.2.8 Assay for Crystalline Surface Guaifenesin 
Melt-extruded tablets containing guaifenesin were assayed for surface crystallized 
drug substance using the procedure described in Figure 7.1. Briefly, individual tablets 
were accurately weighed and a single tablet was placed into a large test tube (25x150 
mm) filled with 5.0 mL of 0.1 N HCl. The test tube was subjected to vortex mixing (SP 
vortex mixer, Baxter Diagnostic, Deerfield, IL) at a fixed agitation force for 5 seconds. 
Immediately after vortex mixing, the medium was decanted and filtered through a 0.22 
micron nylon filter (Puradics 25NYL syringe filter, Whatman, Maidstone, UK). The 
filtered medium containing the dissolved guaifenesin from the tablet surface was 
analyzed by UV analysis. Residual liquid on the recovered tablets was blotted off and the 
tablets were dried at ambient conditions. The dimensions of dried tablets (height and 
diameter) were measured using calipers (Starrett, Athol, MA). Test conditions, including 
immersion time, vortex intensity, vessel size and dilution for the UV test, were chosen to 
ensure discrimination between samples.  
 
7.2.9 Sample Analysis 
The drug content in samples from dissolution testing, drug content analysis and 
recrystallization testing was determined by UV analysis. The guaifenesin content was 
quantified at 273 nm in 400 microliter samples by UV spectroscopy (µQuant UV 
Spectrometer equipped with KC 4 software for data analysis, BioTek Instruments, Inc, 
Winooski, VT). Linearity was established for drug concentrations between 8 and 200 
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ng/mL (R2=0.9968). Concentrations of 2 ng/mL were below the limit of detection of the 
instrument. 
 
DIL was analyzed at 230 nm using the same instrument.  For drug content 
analysis, 50 microliter samples were diluted with 350 microliters of 0.05M phosphate 
buffer pH 6.8. Dissolution test samples were diluted with simulated gastric fluid without 
pepsin in a 1 to 1 ratio. Linearity was established for drug concentrations between 10 and 
200 mg/mL (R2=0.9994).    
 
7.3 RESULTS AND DISCUSSION 
7.3.1 Thermal analysis 
The two drugs were chosen based on their melting points in relation to the 
processing temperatures. Thermal analysis was employed to study the mutual influence 
of the two active ingredients. DSC analysis of guaifenesin-DIL blends was used to 
determine the melting points of guaifenesin (81.2°C) and DIL (215°C, Table 7.3). The 
melting peak of DIL was present in 1:9 blends (guaifenesin:DIL), but was absent from 
the thermogram in 1:1 and 9:1 (guaifenesin:DIL) mixtures. The disappearance of the 
DIL’s melting peak was ascribed to the solubilization of DIL in the guaifenesin melt 
during the analysis. A similar event was reported by Schilling et al, who demonstrated 
that DIL was solubilized by citric acid during melt extrusion (Schilling et al.).  The 
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similarity is plausible given that both citric acid and guaifenesin are small, hydrophilic 
molecules with hydroxy functional groups (-OH) in the alpha position.  
 
 The effect of the drugs on the carrier, Eudragit® L100-55, was measured by 
MDSC (Table 7.4). In the presence of 11.25% guaifenesin, the glass transition 
temperature (Tg) of Eudragit® L100-55 decreased from 125.2 ± 3.67 to 93.8 ± 0.56, both 
for the binary guaifenesin-polymer blend and for the extrusion blend, demonstrating that 
guaifenesin plasticized the polymer as reported earlier (Bruce et al., 2007b). Guaifenesin 
was demonstrated to plasticize other polymers, such as polyethylene oxide (Crowley et 
al., 2004a).  The presence of DIL had no effect on the Tg of Eudragit® L100-55. These 
results demonstrate that when guaifenesin melted at elevated temperatures during 
extrusion, it exerted a plasticizing effect on the polymer, and solubilized the second 
model drug, DIL.  
 
7.3.2 Drug morphology in the extrudates 
 
The macroscopic appearance of the extrudates differed by extruder type: tablets 
produced on the single-screw extruder appeared white and opaque, while extrudates 
processed at 75°C or above on the twin-screw extruder were clear and transparent. 
Materials extruded at 65°C on the twin-screw extruder were more transparent than all 
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extrudates produced with the single-screw extruder, but not as clear as the twin-screw 
products extruded at higher temperatures.  
 
PXRD was employed to study the drug morphology in more detail (Figure 7.2). 
Tablets for PXRD were formulated without DIL to avoid a possible interference of the 
drugs’crystalline peaks. Bulk guaifenesin powder displayed a characteristic crystalline 
spectrum, while the Eudragit® L100-55 powder was amorphous (Bruce et al., 2007a). In 
a physical mixture (the extrusion powder blend, formulation I), lower intensity peaks due 
to crystalline guaifenesin were observed (Figure 7.2 a). The PXRD profiles of all but one 
of the melt-extruded tablets (Figure 7.2 b) showed amorphous characteristics without any 
peaks, and the spectra were of much lower intensity. 
 
The only tablet which displayed crystalline peaks overlaying the amorphous curve 
was extruded on the single-screw extruder at 65°C. This indicated that both amorphous 
and crystalline structures were present, and since all matrix components except for 
guaifenesin were inherently amorphous, the peaks were due to crystalline guaifenesin 
particles present in the matrix. For the crystalline content to be picked up by the method, 
it must have been above the limit of detection for PXRD, between 5 (Kitahara et al., 
2004) and 10% (Schilling et al.). Since the samples were cut from the extrudate just 
before analysis, these peaks were not due to guaifenesin recrystallization. At 65°C, 
processing conditions on the single-screw extruder were evidently not sufficient to melt 
guaifenesin (melting point 79-81°C), and the appearance and PXRD spectra resulted 
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from the distributive and dispersive mixing of crystalline drug particles. At higher 
extrusion temperatures (125°C) on the single-screw extruder, the entire amount of 
guaifenesin, melted during processing, and remained amorphous in the cooled extrudate, 
which resulted in the amorphous spectrum when analyzed by PXRD. Extrusion at higher 
temperatures thus changed the morphology of guaifenesin in the extrudate, and the 
melted guaifenesin plasticized Eudragit® L100-55, which decreased melt viscosity and 
improved mixing. The effects of the melting guaifenesin on the processing conditions are 
presented in Table 7.2. 
 
Crystalline peaks were absent in all formulations extruded on the twin-screw 
extruder, irrespective of temperature. These results demonstrated the higher dispersive 
mixing capabilities of the twin-screw extruder compared to the single-screw extruder. 
The transparency of the tablets produced on the twin-screw extruder indicated that more 
intense dispersive mixing reduced the guaifenesin particle size during extrusion. 
 
7.3.3 Drug distribution in the extrudates 
 
The quality of mixing after melt extrusion was judged by the degree of dispersion 
of the drug in the matrix. Energy-dispersive spectroscopy (EDS) can distinguish and 
locate the chemical elements present in a single point of a specimen, and surfaces can be 
scanned in many points to create a surface map. In addition, the electron beam 
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responsible for producing the signal penetrated a few micron into the sample, the images 
therefore depict the elemental distribution within the penetration depth. EDS has been 
used to study inorganic impurities in paracetamol (Hulse et al., 2008), the itraconazole 
distribution in amorphous compositions (Miller et al., 2008, DiNunzio et al.) and the 
elemental distributions of aluminum, nickel, oxygen and platinum in thin films (Hotovy 
et al., 2001). An active moiety can only be distinguished from its surroundings if it 
contains a chemical element not present in other sample components and if it gives a 
distinct signal in the EDS spectrum. The matrix contained hydrogen, carbon (C) and 
oxygen (O) (due to the Eudragit® L100-55) as well as a small amount of silicon (due to 
silicon dioxide). Guaifenesin lacks a unique atomic species for tracking, thus EDS 
profiling could not be performed on formulation I. Formulation II contained 25% w/w 
diltiazem hydrochloride, and the chlorine atom (Cl) of the salt gave a distinct signal 
which was used for elemental analysis to study the distribution of drug by the two 
extruder types. In general, one to two atomic percent of an element in a sample are 
necessary to detect it by EDS (EDS2006, 2006). The DIL powder was sieved to prevent a 
“false positive” signal of chlorine atoms due to large DIL particles in the matrix, and only 
the particle fraction smaller than 75 micron (200 mesh) was used to prepare the powder 
blends. Since the melting of guaifenesin was considered an important part of the mixing 
process, guaifenesin was incorporated into the tablets for EDS analysis, where it 
functioned as a thermal glidant and solid state plasticizer for Eudragit® L100-55. 
Guaifenesin also solubilized DIL, as was apparent by the disappearance of the melting 
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peak of DIL during DSC analysis (Table 7.3). DIL did not influence the glass transition 
temperature of the acrylic polymer (Table 7.4).  
 
Figure 7.3 and Figure 7.4 show the distribution of carbon and chlorine atoms in 
the matrix, as detected by EDS. The distribution of carbon can be interpreted as depicting 
the matrix. Within the extruded formulation, the chlorine atoms are unique to DIL, and 
thus pinpoint the position of DIL in the matrix. (Trace amounts of Cl were considered to 
be statistically distributed.) Pores in the matrix, identified in the SEM images of the 
scanned area, result in signal interference manifesting in black regions on the EDS map.  
 
Both extrusion temperature and the type of extruder influenced the distribution of 
DIL. The Cl distribution in the formulations extruded at 65°C showed clusters of Cl 
atoms and areas of lower chlorine concentrations (black in the chlorine spectrum, more 
intense yellow in the carbon spectrum), regardless of extruder type. The distribution was 
more homogeneous at 125°C in formulations extruded on the SSE, and the fewest 
chlorine clusters were found in TSE tablets extruded at 125°C. These distributions 
confirm that the degree of mixing improves with processing temperature, and that twin-
screw extrudates were more homogeneous than in single-screw extruded tablets for the 
conditions studied. 
 
The effect of processing temperature on drug distribution can be explained by the 
Tadmore melting model (Tadmor, 1966), which states that initially, melting is the result 
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of sliding friction of solids against the heated barrel, where heat is transferred from the 
barrel to the blend particles. Further downstream, most of the solid materials have melted, 
and unmolten solids are distributed in the melt pool “like ice cubes in water”, and are 
thus isolated by the surrounding melt. At that point, melting becomes less efficient as the 
heat transfer to the remaining solids must be transmitted through the melt as an 
intermediary, which slows the heat transfer. In this context, an increase in the processing 
temperature will promote the melting of all remaining solids by heating the polymer melt 
pool to a higher temperature, which will speed the energy transfer to the suspended 
solids. Increasing the extrusion temperature also reduces the melt viscosity of the melt 
(Allcock et al., 2003), which improves distributive mixing.   
 
7.3.4 Drug content and Dissolution testing  
Neither extruder type nor processing temperature influenced the drug content in 
extrudates (data not shown). The differences in drug distribution on a microscale as seen 
in EDS did not translate into concentration differences in tablets, probably because the 
small-scale differences in drug distribution averaged out in a volume the size of a tablet, 
and the analysis only measured total drug content. The effect of tablet homogeneity on 
drug release was investigated in phosphate buffer pH 6.8. The samples (formulation I) 
contained guaifenesin in Eudragit® L100-55, and were extruded at either 65 or 125°C on 
either a twin-screw extruder or a single-screw extruder. The drug release profiles are 
shown in Figure 7.5, and depended on the tablet dimensions (surface area/volume ratio) 
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of the tablets, which was described for hypromellose matrix tables and water-soluble 
drugs (Reynolds et al., 2002). However, the processing temperatures and the extruder 
type did not influence the drug release. The matrix former Eudragit® L100-55 started to 
dissolve above pH 5.5, so at the pH of the dissolution test, the drug as well as the matrix 
dissolved, obscuring any differences in drug distribution due to the extrusion conditions.  
 
Formulations containing guaifenesin and DIL (formulation II) were used to study 
the effect of processing conditions on the dissolution profile in simulated gastric fluid 
without pepsin, as shown in Figure 7.6. Under acidic conditions, the carboxylic groups on 
Eudragit L100-55 were un-ionized, and the matrix remained intact, which resulted in 
reduced dissolution rates at low pH. However, only the formulation extruded at 125°C on 
the twin-screw extruder released less than 10% drug after 2 hours in acid. The 
homogeneous drug distribution probably maintained the integrity of the tablets, which 
impeded the diffusion of drug located further inside the matrix. Clusters of drug, as seen 
in tablets extruded at 65°C, dissolve to leave behind pores in the matrix. During 
dissolution, the medium will quickly penetrate the entire tablet before drug release is 
observed, as demonstrated by Mäder et al. (Strübing et al., 2007). Dissolving clusters 
could reduce matrix tortuosity by opening up passages for drug molecules to leave the 
tablet and thus shortening diffusion paths. Higher tortuosity is correlated to lower drug 




7.3.5 Recrystallization of guaifenesin from the amorphous state 
Previous studies investigated the physical stability of guaifenesin in melt-extruded 
matrix tablets (Bruce et al., 2007a), which was compromised by the recrystallization of 
guaifenesin from the amorphous state on tablet surfaces. To quantify the development of 
guaifenesin crystals, an assay was developed as the use of x-ray diffraction and DSC to 
quantify surface crystallization were not well suited for the samples in this study. The 
limit of detection for crystalline-in-amorphous samples by powder x-ray diffraction is 5 
(Kitahara et al., 2004) to 10% (Schilling et al.), and thus too high to capture early crystal 
growth. DCS analysis was undertaken without results, since the crystalline guaifenesin 
re-dissolved in the matrix on heating the sample, and the small amounts involved made it 
desirable to study the entire tablet surface area. 
 
Tablets produced by either the single-screw extruder or the twin-screw extruder at 
temperatures between 65 and 125°C were investigated. All tablets were cut from 
extruded rods 24 hours after processing, and were stored in a desiccator (17% relative 
humidity) for the duration of the study, since previous studies demonstrated that moisture 
increased the recrystallization of guaifenesin. 
 
The surface guaifenesin assay measured the amount of guaifenesin that was 
present on tablet surfaces over a 16 day period and was normalized to tablet surface area 
to account for geometric variations in tablet dimensions. It is also important to note that a 
certain amount of amorphous drug was expected to be present on the surfaces of the 
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matrix tablets. To establish a base line, the “day 1” time point was tested immediately 
after tablet preparation to ensure that no surface recrystallization had occurred (at the 
present drug concentration, recrystallization appears within 15-30 minutes). The amount 
of guaifenesin found in the “day 1” analysis was considered to be the amount of 
amorphous drug present on the surface. 
 
Figure 7.7 depicts the amount of surface guaifenesin over 16 days on tablets 
stored at 24°C at 17% relative humidity. The higher the extrusion temperature in the 
single-screw extruder, the less guaifenesin was found in the initial test. Over the 16 day 
study, the amount of surface guaifenesin increased in all formulations, indicating that 
guaifenesin crystals developed on the tablet surfaces. These results are consistent with the 
EDS data showing improved drug distribution at higher processing temperatures, 
resulting in a more homogeneous matrix with lower local drug concentrations. On the 
twin-screw extruded tablets, extrusion temperature did not influence guaifenesin 
recrystallization. Both the initial amounts and the increases in surface crystallization over 
the 16 day study period were lower than in tablets produced on the single-screw extruder. 
The results match the better drug dispersion in twin-screw extruders seen by EDS. The 
exception was the formulation extruded at 65 °C. Though initial surface guaifenesin 
values were comparable to those of the other formulations extruded on the twin-screw 
extruder, it experienced an increase in surface crystal growth similar to the tablets 
extruded on the single-screw extruder at the same temperature. This was attributed to the 
presence of solid guaifenesin in the tablet, which could not be ruled out due to the low 
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extrusion temperature. Twin-screw extrusion may have reduced the particle size, and the 
crystalline content may have been below the detection limit of the PXRD, but very small 
remnants of the solid drug are sufficient to act as a nucleating agent, and cause the 
increase in crystalline guaifenesin.  
 
The difference in surface guaifenesin levels between day 1 and day 16 is 
presented in Figure 7.8, showing the amount of surface crystallization developing over 
the study period. The differences are larger in formulations extruded on the single-screw 
extruder. Formulations which showed a homogenous morphology and drug distribution 
also had lower amounts of drug on the surface in the “day 1 test”, and developed lower 
amounts of surface crystals over 16 days. Two factors influenced the high amounts of 
guaifenesin recrystallization, the presence of solid guaifenesin during processing and the 
degree of mixing. Even small remainders of solid guaifenesin particles in the melt could 
function as nucleants for crystallization in the supersaturated matrix. In the single-screw 
extruder, the extrusion blend was molten as it entered the mixing zone. A higher process 
temperature decreased melt viscosity, enhancing distributive mixing, which improved 
drug dispersion and particle deagglomeration. The resulting lower local supersaturation 







The reciprocal influence of two model drugs, guaifenesin and diltiazem 
hydrochloride, and their effect on melt extrusion, as well as the extrusion of pre-mixed 
powder blends on either a single-screw or a twin-screw extruder and the consequences of 
mixing efficiency for tablet performance were investigated. Thermal analysis revealed 
that guaifenesin affected the extrusion process by plasticizing the polymer, and by 
solubilizing the second model drug, diltiazem hydrochloride. Energy-dispersive 
spectroscopy (EDS) demonstrated that low extrusion temperatures (65°C) resulted in 
heterogeneously mixed tablets for both single-screw extruder and twin-screw extruder. In 
tablets extruded on the single-screw extruder, low extrusion temperature (65°C) was also 
correlated with a partially crystalline drug in the matrix, while all other extrudates were 
amorphous. These differences in drug morphology and level of mixing had consequences 
for the physical stability of the tablets. Surface recrystallization of guaifenesin was higher 
in tablets extruded on the single-screw extruder, and decreased with increasing 
processing temperature. Surface crystal growth in tablets extruded on the twin-screw 
extruder was independent of processing temperature, except for those extruded at 65°C. 
Better mixing resulted in homogeneous tablets without drug clusters, which reduced local 
supersaturation levels. Higher matrix homogeneity therefore reduced the driving force for 
crystallization. Higher processing temperature and more intense mixing promoted the 
complete melting of the extrusion blend. The absence of guaifenesin crystals in the 
matrix made them unavailable to act as nucleants, which can reduce the induction time of 
crystal growth. In conclusion, extruder type affected the properties of melt-extruded 
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tablets, and control of the processing conditions can be used as a strategy to increase the 
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Table 7.1 Formulation compositions. 
 
Formulation Component Function % 
I Guaifenesin Model drug 37.5 
 Colloidal Si O2 Glidant 0.5 
 Eudragit® L100-55 Matrix former 62 
II Diltiazem HCl Model drug 25 
 Guaifenesin Model drug 11.25 
 Colloidal SiO2 Glidant 0.5 









Table 7.2 The influence of extrusion temperature on processing conditions  
 
The extrusion blend consisted of formulation I.  
 
Single-Screw Extruder Twin-Screw Extruder Extrusion Temperature 
(°C) 
RPM DriveAmps RPM DriveAmps 
65 1.5 649 50 280 
75 20 266 200 345 
85 20 220 200 276 
95 20 145 200 235 







Table 7.3 The melting points of guaifenesin and diltiazem hydrochloride, pure and 
in powder blends with each other. 
 
DSC, heating rate 10°/min, 50-230°C, n=3, average reported. 
 
Powder Blend Peaks detected (°C) 
Guaifenesin  81.2±0.6                               -- 
Diltiazem HCl  --                             215.4±0.3 
Guaifenesin: Diltiazem HCl  1 : 9 79.0±2.0                  203.5±1.4 
Guaifenesin: Diltiazem HCl  1 : 1 79.4±0.3               not detected 










Table 7.4 The influence of guaifenesin and diltiazem hydrochloride on the glass 
transition temperature of Eudragit® L100-55.  
 
All samples were powders, MDSC, heating rate 15°C/min, temperature amplitude 
0.5°C every 40 sec, 50-170°C, 2nd run, n=3. 
 
Sample Glass Transition Temperature, °C 
Eudragit® L100-55 125.2 ± 3.67 
25% Diltiazem HCl in Eudragit® 
L100-55 
125.9 ± 0.52 
11.25% Guaifenesin in Eudragit® 
L100-55 
93.8 ± 0.56 
Extrusion Blend* (formulation II) 94.8 ± 2.12 
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Figure 7.2 a. Powder x-ray diffraction profile of powdered guaifenesin and the 
physical mixture.  
 
Step size 0.02°, dwell time 2.0 sec. 
  


























Figure 6.2 b. The influence of extruder type and temperature on the morphology of 
guaifenesin. 
 
Formulation I, step size 0.02°, dwell time 2.0 sec. 
 
A - Single-screw extrusion,   65°C 
B - Single-screw extrusion, 125°C 
C - Twin-screw extrusion,     65°C 














Figure 7.3 a. The effect of single-screw extrusion at 75°C on the diltiazem 
hydrochloride distribution in melt-extruded tablets (formulation II). 
 
C – EDS mapping of the carbon present in the sample 
Cl – EDS mapping of the chlorine present in the sample 












Figure 6.3 b. The effect of single-screw extrusion at 125°C on the diltiazem 
hydrochloride distribution in melt-extruded tablets (formulation II). 
 
C – EDS mapping of the carbon present in the sample 
Cl – EDS mapping of the chlorine present in the sample 










Figure 7.4 a. The effect of twin-screw extrusion at 75°C on the diltiazem 
hydrochloride distribution in melt-extruded tablets (formulation II). 
 
C – EDS mapping of the carbon present in the sample 
Cl – EDS mapping of the chlorine present in the sample 









Figure 6.4 b. The effect of twin-screw extrusion at 125°C on the diltiazem 
hydrochloride distribution in melt-extruded tablets (formulation II). 
 
C – EDS mapping of the carbon present in the sample 
Cl – EDS mapping of the chlorine present in the sample 








































Figure 7.5 The influence of extruder type and processing temperature on the release 
of guaifenesin from melt-extruded tablets.  
 
Formulation I, basket method, 50 RPM, 900 mL, phosphate buffer pH 6.8, 37°C, 
n=3. 
 
◊  - Single-screw extrusion,  65°C extrusion temperature 
 - Single-screw extrusion, 125°C extrusion temperature 
∆ - Twin-screw extrusion,  65°C extrusion temperature 




































Figure 7.6 The influence of extruder type and processing temperature on the release 
of diltiazem hydrochloride from melt-extruded tablets.  
 
Formulation II, basket method, 50 RPM, 900 mL, simulated gastric fluid without 
pepsin, 37°C, n=3. 
 
◊  - Single-screw extrusion,  65°C extrusion temperature 
 - Single-screw extrusion, 125°C extrusion temperature 
∆ - Twin-screw extrusion,  65°C extrusion temperature 
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Figure 7.7 The influence of extruder type on the recrystallization of guaifenesin 
from melt-extruded tablets containing 37.5% guaifenesin in a matrix composed of 
Eudragit® L100-55.  
 
Formulation I, storage in open containers, 21°C, 17% relative humidity, n=6. 
 
A - Tablets extruded on single-screw extruder 
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 Figure 7.8 The amount of guaifenesin crystal growth developing between day 1 and 
day 16 in melt-extruded tablets containing Eudragit® L100-55 and guaifenesin  
 
Tablets consisted of formulation I. The results from the surface guaifenesin assay 







Chapter 8: Summary and Conclusions 
 
8.1 CONCLUSIONS OF SUPPORTING OBJECTIVES 
 
Acryl-EZE® and Eudragit L100-55® were successfully extruded with guaifenesin as 
the model drug. Guaifenesin had a plasticizing effect on the acrylic polymer, and formed 
a solid solution in the acrylic polymer during processing. At a 25% drug loading, the 
saturation solubility of the guaifenesin in the Eudragit L100-55® was exceeded after the 
extrudate was cooled to ambient conditions, resulting in crystal formation at the surface 
of the tablet. The addition of hydrophilic polymers to the matrix reduced the onset and 
the extent of drug recrystallization.  
 
Supporting objective II investigated the influence of heterogeneous crystallization 
due to relative humidity in storage and talc as a formulation component on the amount of 
guaifenesin recrystallizing on the surface of melt-extruded matrix tablets. Tablets 
contained a constant guaifenesin-to-polymer ratio in a matrix of either Acryl-EZE® or 
Eudragit® L100-55 and either no talc, 25% or 50% talc. Even at low supersaturation 
levels, talc-containing extrudates developed recrystallization earlier, as talc induced 
nucleation as nucleating agent. At higher drug levels (37.5:62.5 drug to polymer ratio), 
the presence of talc increased the quantity of drug crystals on tablet surfaces after for 15 
days (storage at 24°C and 17%RH). No concentration-depended effect of talc on the drug 
recrystallization was found, probably because both talc levels were above the critical 
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nucleant concentration. Lower than expected crystal growth on Acryl-EZE®-containing 
matrix tablets demonstrated that the effects of several non-melting components were not 
additive. Relative humidity increased guaifenesin crystallization in tablets with and 
without talc, but recrystallization did not correlate with increased moisture uptake, 
indicating heterogeneous nucleation as a probable cause for this observation. Results 
from tablets stored transiently under high or low humidity conditions demonstrated the 
effect of relative humidity in storage on guaifenesin recrystallization was due to its effect 
on nucleation. The guaifenesin crystals, once they were induced, remained on tablet 
surfaces regardless of subsequent changes in storage relative humidity. This is an 
important consideration when working with intermediates and finished products 
containing amorphous components which might recrystallize. Formulation components 
and relative humidity conditions had no effect on the composition of surface guaifenesin 
crystals. Mass spectrometry indicated all crystalline samples recovered from stored 
tablets were identical to guaifenesin bulk material. In conclusion, both talc in the 
formulations and humidity during storage increased surface crystallization of guaifenesin 
by heterogeneous nucleation. 
 
Supporting objective III investigated the effect of film-coating on the 
recrystallization of guaifenesin. The film-coating of hot-melt extruded acrylic matrix 
tablets containing guaifenesin was investigated. Film-coating delayed the onset of 
crystallization over uncured tablets regardless of the polymer used for the coating, 
probably by protecting the amorphous drug from ubiquitous nucleating agents. The drug 
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morphology of guaifenesin crystals was altered due to the presence of polymers. Most 
formulation and processing factors investigated (polymer type; weight gain; curing time 
and temperature; storage conditions; and core drug-to polymer ratio) all effect a single 
variable: diffusion. A variable promoting either guaifenesin or the polymer diffusion 
resulted in an earlier onset of recrystallization. The choice of coating polymer was the 
largest single factor affecting the onset time of crystallization. In conclusion, the film-
coating of hot-melt extruded, acrylic matrix tablets successfully delayed the onset of 
guaifenesin recrystallization for up to 6 months. 
 
The extrusion of pre-mixed powder blends on either a single-screw or a twin-screw 
extruder, effects of guaifenesin and diltiazem hydrochloride on each other and the 
polymer during thermal treatment, and the consequences of mixing efficiency for tablet 
performance were investigated in supporting objective IV. Thermal analysis showed that 
guaifenesin solubilized the high-melting drug diltiazem hydrochloride, and that it 
plasticized the polymer. EDS demonstrated that low extrusion temperatures (65°C) 
resulted in heterogeneously mixed tablets for both single-screw extruder and twin-screw 
extruder. In tablets extruded on the single-screw extruder, low extrusion temperature 
(65°C) was also correlated with a partially crystalline drug in the matrix, while all other 
extrudates were amorphous. These differences in drug morphology and level of mixing 
had consequences for the physical stability of the tablets.  Surface recrystallization of 
guaifenesin was higher in tablets extruded on the single-screw extruder, and decreased 
with increasing processing temperature. Surface crystal growth in tablets extruded on the 
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twin-screw extruder was independent of processing temperature, except for those 
extruded at 65°C. Better mixing resulted in homogeneous tablets without drug clusters, 
which reduced local supersaturation levels. Higher matrix homogeneity therefore reduced 
the driving force for crystallization. Higher processing temperature and more intense 
mixing promoted the complete melting of the extrusion blend. The absence of 
guaifenesin crystals in the matrix made them unavailable to act as nucleants, which can 
reduce the induction time of crystal growth. In conclusion, the extruder type affected the 
properties of melt extruded tablets, and control of the processing conditions can be used 
as a strategy to increase the physical stability and modify the dissolution properties for 
melt extruded dosage forms.   
 
8.2 OVERALL CONCLUSION 
 
This study demonstrated that the recrystallization of guaifenesin from the amorphous 
state in melt-extruded tablets depended on the solubility of the drug in the matrix. 
Polymer blends of Eudragit® L100-55 with hydrophilic polymers reduced 
recrystallization by extending the guaifenesin solubility in the matrix blend. Formulation 
factors, such as the presence of talc in the matrix, and storage conditions, such as the 
relative humidity during storage, promoted the recrystallization by a nucleating effect. 
Film-coating of tablets delayed the onset of crystallization by modifying the surface of 
matrix tablets, where recrystallization occurred. The selection of the coating polymer had 
the largest impact in determining the delay in the onset of guaifenesin recrystallization, 
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but all factors which influence diffusion can be used to prolong the physical stability. The 
degree of drug dispersion achieved by melt-extrusion differed between extruder types, 
and was demonstrated to be a factor in determining the quantity of recrystallization. In 
conclusion, to maximize the physical stability of amorphous drugs in melt-extruded 
dosage forms, the study identified several options, which function by different 
mechanisms, and which can be applied concurrently. The processing equipment, post-
processing modifications of the dosage form, formulation components and their mutual 
solubilities, as well as storage conditions were all demonstrated to influence the physical 
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